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ABSTRACT 
Understanding the environmental factors influencing virulence of V. vulnificus is 
of utmost importance in reducing human exposure to this deadly pathogen. Quantitative 
PCR assays for the virulence indicator genes vcg and 16S rRNA type A/B were used to 
examine fluctuations in virulence with season in Galveston Bay oysters. A strong 
seasonal shift of V. vulnificus strain types was observed. Environmental strains (16S 
rRNA type A) predominated from April to mid-June as temperatures rose 20 to 28°C 
and salinities increased from 22 to 27 PSU. As temperatures increased to ≥30°C from 
mid-June to September and salinities rose above 27 PSU, clinical strains (16S rRNA 
type B; vcgC) predominated.  
Enrichment media was tested for selective enrichment for environmental or 
clinical strains from seawater. Ratios of clinical to environmental strains enriched in 
alkaline peptone water (APW) remained constant, however Brain Heart Infusion Broth 
(BHIB), with its higher iron content, preferentially enriched for clinical strains indicating 
that iron plays an important role in the infection of the human host.  
Biofilm formation by clinical and environmental reference strains of V. vulnificus 
were tested under different temperature pH and iron concentration conditions. Clinical 
strains were found to produce significantly more biofilm than environmental strains at 
24°C versus 30°C or 37°C. There was a significant trend for clinical strains of V. 
vulnificus to form more biofilm at acidic pH (5.5) than environmental strains, at both 
24°C and 37°C, indicating that biofilm may be important for survival of clinical strains 
in the gastrointestinal tract of the human host. There was a strong, direct correlation 
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between iron concentration in the growth medium and biofilm production by all strains 
tested. With regards to temperature and pH, higher biofilm production appears to be a 
trait of clinical strains and could be considered a virulence factor.  
Examination of genes encoding for virulence factors hemolysin/cytolysin and 
capsular polysaccharide during biofilm formation revealed that their expression was 
influenced by maturity of the biofilm as well as by temperature. Both genes were up-
regulated during biofilm formation indicating that biofilm may be the preferred form of 
V. vulnificus in the human host. 
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NOMENCLATURE 
 
CPS Capsular polysaccharide 
DNA Deoxyribonucleic acid 
h Hour 
LPS Lipopolysaccharide 
OD Optical density 
PCR Polymerase chain reaction 
qPCR Quantitative PCR 
PSU Practical salinity units 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
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CHAPTER I 
 
INTRODUCTION 
Vibrio vulnificus are Gram-negative, motile, halophilic curved rod-shaped 
bacteria which naturally reside in coastal marine environments worldwide. It is 
considered as one of the most invasive and fatal pathogenic bacteria to humans and has 
been isolated from water, sediments, shellfish such as oyster, mussels, shrimp, fish, and 
clams (1-7). Even if the number of V. vulnificus infected individuals is lower than that of 
other vibrios, it accounts for 95% of all seafood related deaths in the United States, and 
causes the highest death rate of any foodborne disease (8-11). It is the causative agent of 
two types of diseases, fulminant primary septicemia and necrotizing wound infections. 
The type of disease and the number of deaths depend on the route of transmission. 
Consumption of raw or undercooked seafood containing a high enough concentration of 
V. vulnificus can cause primary septicemia with a death rate exceeding 50% in people 
having an underlying disease, in particular diseases that elevate serum blood levels such 
as hemochromatosis, liver cirrhosis, and diabetes (11, 12). It can also cause severe 
wound infections by exposure of pre-existing wounds to seawater harboring this 
bacterium, with a mortality rate up to 25% (2, 13). The majority of cases results in death 
within 24-48 hours. Interestingly, males are more susceptible to this bacterium than 
female and most (95%) of cases have been observed in males, because estrogen provides 
protection against V. vulnificus endotoxin in females (14).  
 2 
 
 
General ecology and distribution depend on several factors, including 
temperature, salinity, dissolved organic matter, oxygen, and pH, but it has been reported 
that temperature and salinity are the most important determinant affecting the occurrence 
of V. vulnificus (15-17). V. vulnificus is halophilic and is most prevalent in seawater 
having salinities between 5 and 25 PSU (18, 19). And, it grows best at temperatures 
between 10°C and 30°C (16, 19). This bacterium encounters several environmental 
stresses in its natural habitat, such as high or low temperature, limited nutrient 
availability, oxidative stress, and fluctuations in salinity. To cope with these challenges, 
V. vulnificus enters a viable-but-nonculturable state (VBNC), especially during cold 
temperatures below10°C (20). V. vulnificus in the VBNC state are not able to grow, even 
on nutrient rich medium, so the incidence of infection is almost zero during the winter 
(21). Most cases of infection happen between May and October when seawater 
temperatures typically range between 20°C and 30°C (22).  
V. vulnificus exhibits varied degrees of virulence. Strains isolated from hospital 
patients, referred to as ‘clinical,’ are highly virulent, whereas strains isolated from 
seawater, oysters, and other marine life are typically less virulent (23, 24). One of the 
first studies (23) to observe differences in virulence of clinical versus environmental 
strains using iron-overloaded mice found that environmentally isolated strains required a 
350-fold higher inoculum than clinical strains for infection. And, death occurs more 
frequently in patients infected with clinical strains rather than environmental strains (25-
27). 
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Although the pathogenic mechanism of this bacterium has not been thoroughly 
elucidated, various virulence factors have been identified such as capsular 
polysaccharide (CPS) (28), lipopolysaccharide (LPS) (29), iron uptake system (30), pili 
(31), flagella (32), outer membrane proteins (33), rtxA toxin (34), hemolysin/cytolysin 
(35) and metalloprotease (36). Even though all of these virulence factors facilitate the 
virulence of V. vulnificus, CPS is considered the most important virulence determinant 
because it provides protection from the non-specific host immune system (37).  
Molecular typing methods for several virulence markers have been developed to 
distinguish between clinical and environmental strains (38-42). Some of these virulence 
markers such as LPS (29), CPS (41), flagella (32), hemolysin/cytolysin (43) and 
metalloprotease (44) cannot completely distinguish the clinical from environmental 
strains. However others, such as 16S rRNA (type A and B) (40), the viuB gene that 
encodes for vulnibactin (siderophore) (41) and the virulence correlated gene (vcg) (39), 
are have shown promise. 
Chapter II of this dissertation is an in depth literature review of V. vulnificus 
ecology disease, virulence, and biofilm formation. 
Chapter III evaluates the application of two virulence factor genotypes, 16S 
rRNA (type A and B) and the clinical variant of the vcg gene, to study the seasonal 
variation of clinical and environmental strains of V. vulnificus in oysters. 16S rRNA type 
B is associated with clinical strains and type A with environmental strains. Good 
agreement was observed by Nilsson et al. (25) who examined clinical isolates from 
patient fatalities (94% type B), patient recoveries (50% type B), and environmental 
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strains from oysters or seawater (94% type A). Vcg has two sequence variants, vcgC and 
vcgE. The vcgC variant has a 90% accurate detection rate for known clinical isolates 
whereas the vcgE variant has an 87% detection rate for known environmental isolates 
(39). The following hypotheses were tested: 
H0: There is no seasonal variation in populations of clinical and environmental 
strains of V. vulnificus;   
H1: The vcgC gene, a highly accurate indicator of clinical strains in isolate 
cultures, can accurately detect clinical strains in environmental samples.   
Chapter IV tests liquid media typically used to maintain V. vulnificus isolate 
cultures or to enrich for V. vulnificus prior to plating on selective-differential agars for 
selective enrichment of clinical versus environmental strains. Standard isolation methods 
for V. vulnificus involve a prior enrichment step with Alkaline Peptone Water (APW) 
followed by streaking onto selective-differential agars. The question is whether APW 
selects preferentially for clinical or environmental strains. The following hypotheses 
were tested: 
H1: APW does not select equally for clinical and environmental strains thereby 
altering the isolation rate of each on selective-differential agars.  
H2: Brain Heart Infusion Broth with its high iron content selects preferentially for 
clinical strains similar to the human host. 
Chapter V examines environmental factors that affect formation of biofilms by 
V. vulnificus. Due to the nature of infections (i.e. blood or wounds), biofilm production 
by V. vulnificus has been largely ignored except for a few studies that identified genes 
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responsible for biofilm formation (31, 45-48). Most studies of biofilm formation in 
vibrios have been conducted with V. cholerae. V. cholerae forms robust biofilms in the 
aquatic environment (49), and in response to bile acids in the gastrointestinal tract (50). 
The following hypotheses were tested: 
H1: Similar to V. cholerae, V. vulnificus will produce more biofilm at acidic pH 
than at neutral or alkaline pH. 
H2: V. vulnificus will produce more biofilm at 37°C, the temperature of its human 
host.  
Chapter VI examines the expression of hemolysin/cytolysin (vvhA) and CPS 
operon (CPS allele 1) genes during biofilm formation by V. vulnificus to determine if 
either are affected by biofilm production. It has been demonstrated that V. cholerae is 
more virulent in biofilm than in its planktonic form (49, 50). While, CPS, the most 
important virulence factor, provides protection from the non-specific host immune 
system (37) it may also be an important component of biofilm in V. vulnificus (51). 
However, Joseph and Wright (45) found that CPS expression inhibits biofilm formation 
in V. vulnificus. The following hypotheses were tested: 
 H1: V. vulnificus expression of the hemolysin/cytolysin gene (vvhA) will be 
higher during biofilm formation than in planktonic cells. 
H2: Expression of CPS allele 1 will be suppressed during biofilm formation and 
increased in planktonic forms of V. vulnificus.  
Chapter VII is a summary of the four studies. 
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CHAPTER II 
 
LITERATURE REVIEW 
Vibrio vulnificus ecology 
V. vulnificus occurs naturally in estuarine and coastal waters worldwide. It can be 
isolated from shellfish, especially oyster, mussels, clams, fish, shrimp and sediments (1, 
2, 6, 7, 22). Temperature and salinity are the most important factors affecting the 
distribution of V. vulnificus. Concentration of V. vulnificus in seawater and oysters 
fluctuate with seasonal temperature changes. Typically, during the winter when seawater 
temperatures fall below 10°C V. vulnificus is almost undetectable (5, 52, 53) and it enters 
a state of viable-but-nonculturable (20). As seawater temperature increases above 10°C 
in spring months and approaches 25°C in the early summer the concentration of V. 
vulnificus increases to ~10
1
- 10
2
 CFU/ml and can reach 10
3
 CFU/ml when seawater 
temperatures rise above 25°C during summer months (16, 19, 53). V. vulnificus is not 
able to multiply in oysters at 13°C or lower temperatures and concentrations are 
typically ≤ 10 CFU/g oyster meat (15, 54) but during warmer months, as temperatures 
reach 25°C and above, concentrations increase to >10
3
 CFU/g (15).   
Highest V. vulnificus concentrations (10
3
 CFU/ml) can be detected in seawater 
with salinity from 5 to 30 PSU (19). The highest number in oysters (>10
3
 CFU/g) 
typically occurs at salinities between 5 and 25 PSU but concentrations decrease at higher 
salinities (15). 
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Early clinical investigations 
 Hollis et al. (55) with the Special Bacteriology Section of the Centers for 
Disease Control (CDC) in Atlanta, Georgia, published the first clinical description of V. 
vulnificus from extensive diagnostic biochemical testing of 38 strains of “unnamed 
marine Vibrio.” Most were obtained over a period of 11 years from medical case studies 
in 15 US states (seven in LA, six in FL, five in AL, four in TX, four in RI, two in HI, 
two in VA, one in NC, one in AR, one in GA, one in CA, one in SC, one in WI, one in 
MA, and one in PA). The strains were isolated from blood (20 cases), spinal fluid (2 
cases), and localized limb infections (16 cases). Patients recently had either ingested 
raw/undercooked seafood (56) or been exposed to seawater (57-59). Prior to testing at 
the CDC, it was widely speculated that this new vibrio was a “biotype” of V. 
parahaemolyticus, (60) or V. alginolyticus,, referred to then as “V. parahaemolyticus 
biotype 2 (alginolyticus)” (61). However, unlike either of these vibrios, this new strain 
was capable of lactose fermentation and thereafter was referred to as “lactose positive” 
(55) until it was taxonomically described and formally give the name “Vibrio vulnificus” 
(62, 63). 
 Galveston Bay (Texas) figured prominently in these early investigations of V. 
vulnificus. Of the 38 ‘clinical’ strains tested by the CDC (55), four from Texas were 
isolated from patients who had become ill after exposure to seawater in Galveston Bay 
and the nearby Gulf of Mexico (58). Just a few years later, after several cases of 
bacteremia (two fatal) on Galveston Island, a 12 month study was initiated to determine 
the distribution and occurrence of V. vulnificus at 21 sites typically frequented by 
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tourists and local inhabitants (64). Sites located on the bay side of the island, including 
the ferry landing, ship harbor, bayou, and yacht basin, were 67 to 100% positive for V. 
vulnificus throughout the study period whereas beach sites on the open gulf side of the 
island had significantly lower occurrences (0 to 17%). The more enclosed yacht basin 
and ship harbor had the highest occurrence rates of 71 and 100%, respectively. Seven 
‘environmental’ strains originating from this study were later used by Johnson and Calia 
(65) in the first tests for hemolytic activity. No bacteriological differences were observed 
between ‘clinical’ (three fatal bacteremia, one non-fatal bacteremia) plus another 
isolated from an oyster, and the ‘environmental’ strains. However the clinical strains 
demonstrated significantly greater serum resistance (a zero decline of log10 CFU after 2 
hr vs. 2.6 log10 decline of CFU in environmental strains) as well as virulence (1,000 
times lower LD50 than environmental strains) in orogastric challenge tests with suckling 
mice (66).  
In the 25 years that have followed, characterization of V. vulnificus has taken 
divergent paths: 1) medical diagnosis 2) molecular identification of virulence factors for 
development of antibiotics and vaccines, 3) seafood safety for the prevention of illness, 
and 4) ecological to understand the environmental conditions for growth and virulence. 
  
Vibrio vulnificus disease 
V. vulnificus accounts for 95% of all seafood related deaths in the United States, 
and causing the highest-death rate of any food-borne disease (8, 21). Forms of illness 
after ingestion of V. vulnificus are typically gastrointestinal (gastroenteritis) presented as 
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vomiting, diarrhea, and severe abdominal pain, but if not treated, can rapidly infect the 
bloodstream (septicemia) within 24 to 48 hr resulting in fever, chills, blistering skin 
lesions (bullae), tissue necrosis, and death (2, 13, 67). Infections can also be caused by 
exposure of pre-existing or fresh wounds to seawater containing V. vulnificus or by 
handling seafood (2). Both the type of disease and the number of deaths depend on the 
route of transmission. The mortality rate for primary septicemia, the most lethal form of 
infection, is greater than 50% after consumption of raw or undercooked oysters having 
high enough titers of V. vulnificus cells, and it can result in higher mortality rate in 
people who are immuno-compromised or have an underlying disease such as cancer, 
diabetes, hepatic disorders, hemochromatosis, thalassemia, and alcoholism (12). The 
leading cause of septicemia in those immunocompromised people is due to the elevated 
iron levels in blood. People with compromised immune systems or chronic liver disease 
are also at risk and 80 times more likely than healthy people become septicemic (68). 
However, primary septicemia is quite rare in healthy individuals. After first indications 
of infection, death from septicemia typically occurs within one or two days (37, 68). 
Exposure of pre-existing or fresh wounds to seawater containing V. vulnificus can also 
lead to infection and a 25% mortality rate in people with wound infections has been 
observed (13). Wound infection is thought to occur as a consequence of seafood 
handling, fishing, boating, swimming, or wading (2, 67). Most cases of wound and 
ingestion infection happen between May and October when the temperature of seawater 
is warmer (20°C to 30°C) (22). 
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Isolation and detection methods 
In the clinical setting V. vulnificus from tissues and blood are isolated on blood 
agars (69). Standard methods for enumeration and isolation of V. vulnificus from 
environmental samples involve enrichment in Alkaline Peptone Water (APW) followed 
by streaking onto selective differential agars. Several media agars have been developed 
such as thiosulphate citrate bile salts sucrose TCSB (70) sodium dodecyl sulfate-
polymyxin B-sucrose agar (SPS) (71), V. vulnificus (VV) agar (72), V. vulnificus 
enumeration medium (VVE) (73), V. vulnificus medium (VVM) (74), cellobiose 
polymyxin B colistin (CPC) agar (73), modified mCPC (75). Cultivation based-detection 
and enumeration methods do not meet the necessary sensitivity and specificity 
reliability, therefore identification of the strains is followed by biochemical, 
immunological assays (75), DNA probes (76) and most recently-developed molecular 
polymerase chain reaction (PCR) assays (77). 
A quantitative real-time PCR based on TaqMan oligonucleotide fluorogenic 
probe targeted on V. vulnificus hemolysin/cytolysin-encoding gene, vvhA, has been 
developed for direct detection and enumeration of V. vulnificus with a detection 
threshold of 6 CFU per PCR assay or 72 fg per microliter of PCR mixture from pure 
cultures (78). Probe-based quantitative real-time PCR makes use of a specific 
hybridization probe having a reporter fluorescent dye at 5’ end and a quencher molecule 
at 3’end. When the probe is in its native state no fluorescence is emitted, because the 
quencher molecule absorbs the emission of reporter dye due to the close proximity of 
both molecules, but during amplification the 5’-3’ exonuclease activity of Taq 
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polymerases releases the reporter from the vicinity of quencher and causes an increase in 
fluorescence (79). SYBR Green I-based real-time quantitative PCR assay was described 
based upon vvh-specific oligonucleotide primers with the detection rate equivalent to 1 
pg of purified DNA or 10
2
 cells in 1 g of unenriched oyster homogenate or 10 ml of 
seawater samples (80). SYBR Green I based RT-PCR assay utilizes fluorogenic, DNA 
intercalating SYBR green dye which binds the minor grove of double stranded DNA 
during amplification of the products of interest, and the biggest advantage of this assay is 
the use of any primer set which can, if optimally designed, can preclude non-specific 
targets in the reaction mixtures (79, 81). The drawback of SYBR green dye is the 
binding of any dsDNA of target and non-target products, which can be overcome by 
melting curve analysis the melting curve peaks of which will differ in target and non-
target amplicons (79). 
 
Classification systems for strains 
Classification of V. vulnificus is currently based on 1) biotype, 2) genotyping, 
and 3) virulence factors such as siderophore production, lipopolysaccharides (LPS), 
capsule polysaccharides (CPS), and hemolytic/cytolytic enzymes. 
 
Biotypes. V. vulnificus strains have been more formally divided into three 
distinct biotypes based upon their biochemical and phenotypic characteristics (68). 
Biotype 1 strains are almost completely related to human disease and generally found in 
association with seawater and shellfish. These strains are positive for indole and 
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ornithine decarboxylase production and produce many immunologically different types 
of LPS. Biotype 2 strains mainly cause disease in marine vertebrates, especially in eels, 
and are not able to produce indole and ornithine decarboxylase and produce only a single 
type of lipopolysaccharide (LPS), designated as “serogroup E,” A third biotype, Biotype 
3 was identified in Israel as strains isolated from wound infections and septicemic 
individuals that handle cultured tilapia (2). Comparison of these three biotypes based on 
genetic analysis has revealed that Biotype 3 is a hybrid of Biotypes 1 and 2 and 
phenotypically differs from them by the inability to ferment salicin, cellobiose, and 
lactose (68). 
 
Genotyping. Several genes that differentiate clinical versus environmental 
strains have been identified—16S rRNA (type A/B), virulence correlating gene (vcg), 
siderophore gene (viuB), pilus-type IV gene (pilF), and capsulated polysaccharide (CPS 
alleles 1 and 2).  
The 16S small subunit (SSU) ribosomal ribonucleic acids (rRNA), 23S large 
subunit (LSU) rRNA, and the interspacer (ITS) region between these two genes allows 
for differentiation between clinical and environmental strains. Analysis of 16S rRNA 
determined that the “B type” was indicative of clinical strains whereas environmental 
strains were “A type” (38, 82). Using terminal restriction length polymorphism (TRFLP) 
and quantitative PCR, Vickery et al. (27) was able to positively identify 97% of known 
environmental isolates (from oysters and water) as 16s rRNA type A, however 29% of 
these were later determined to be both type A and B. And, they determined that 76% of 
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known clinical strains were type B, with 14% of these being both type A and B. 
Interestingly, the majority of the type A/B clinical strains were isolated from patients 
who recovered from V. vulnificus infection whereas the type B strains were isolated from 
patient fatalities. Typing analysis of conserved sequences located between the 16S and 
23S rRNA genes (interspacer region) revealed that clinical and environmental strains can 
be grouped into a single clusters, the first consisting of highly similar clinical strains of 
type B but the cluster of environmental strains is a combination of type A and B (83). 
The virulence correlating gene (vcg), a 200 bp noncoding region identified by 
Rosche et al. (39) with random amplified polymorphic DNA (RAPD) PCR has two 
sequence variants—one that occurs primarily in clinical strains (vcgC) and another that 
occurs primarily in environmental strains (vcgE). Rosche determined a 90% 
identification rate for vcgC with known clinical strains and a 93% rate for vcgE with 
known environmental strains.  
Siderophore production differs between virulent and less virulent V. vulnificus 
strains. Panicker (84) identified a 504 bp gene, viuB, that encodes for the siderophore 
vulnibactin in V. vulnificus. The viuB gene was found to occur in 100% of known 
clinical isolates tested and in only 24% of known environmental isolates tested. 
However, another study (41) analyzed 349 V. vulnificus oyster isolates for 
presence/absence of the viuB gene and found that only 41% of known clinical strains 
tested positive indicating that this gene is not reliable for differentiation. 
Roig et al. (42) proposed that the polymorphism in pilF gene encoding for pilus-
type IV can be used as a virulence marker to distinguish less virulent environmental 
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strains from more virulent clinical strains of V. vulnificus, regardless of the biotypes of 
strains. Baker-Austin (85) later developed a quantitative PCR assay for the clinical 
variant of the pilF gene and found a 97.9% association with known clinical strains.  
The group 1 capsular polysaccharide (CPS) operon has two genotypes, allele 1 
that corresponds to clinical strains and allele 2 to environmental strains (86). Allele 1 
was found in clinical isolates 63.6% of the time and in environmental isolates 36.4% of 
the time. Allele 2 was found in environmental isolates 71.4% of the time and in clinical 
isolates 20% of the time. And, neither allele was present in 8.6% of environmental 
strains (24). Another study showed that the CPS allele 1 had a 60% detection rate in 
clinical isolates and allele 2 had a 50% detection rate in environmental isolates (41).  
Traditional and quantitative PCR assays have been developed for these 
genotypes (Table 1). 
 
Virulence factors and pathogenicity 
Johnson et al. (66) conducted one of the earliest studies of virulence studies using 
the original, and not yet named, strains isolated from infected individuals, i.e. “clinical” 
and seawater, i.e. “environmental.” Individual isolates were inoculated onto blood agar 
plates to determine susceptibility to bactericidal properties in human blood serum. Most 
of the clinical strains demonstrated a significantly greater resistance, or survival rate, to 
human blood serum than environmental strains. No observable die off, or decline, of 
colony forming units (CFU), expressed as “log10,“ occurred in the clinical strains versus 
an average 2.6 decline of log10 CFUs among environmental strains after a 2 hr exposure 
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to the sera. The same study observed significantly higher virulence (1,000×) in clinical 
strains than for the environmental strains during orogastric challenge tests involving 
inoculating the mouths and stomachs of suckling mice with a dilution series of each 
isolate.  However, in a previous study with the same isolates, Johnson and Calia (65) 
observed no statistical difference in hemolytic activity between strains from infected 
individuals or the environment. A more recent study showed that colony opacity was a 
reliable predictor of virulence in V. vulnificus strains, regardless of clinical or 
environmental source (87). Without exception, opaque colonies, differentiated from 
translucent colonies when grown on heart infusion agar, were lethal to adult mice at 
LD50  of 10
9 
 (in 0.5 ml intraperitoneal injections) and addition of Fe
3+
 (as ferric 
ammonium citrate) lowered the LD50  to 10
3
, indicating that iron availability strongly 
influences virulence (87). Translucent colonies never caused fatalities, even with 
addition of iron.  
Subsequent studies during the past 25 years have identified several factors 
influencing the degree of virulence in V. vulnificus. It is also becoming increasing 
evident that these factors, when present singly or in combination, confer highly variable 
degrees of virulence 
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Table 1. Genotyping PCR assays for virulence factors and type strains 
Primer/ 
Probe Target 
Strain 
Specificity Primer Sequence (5'-3') Assay Ref. 
P1 vcg  
C/V1, Biotype 
1 AGC TGC CGA TAG CGA TCT qualitative (39) 
P3 
  
CGC TTA GGA TGA TCG GTG 
  
P2 
 
E/A2, Biotype 
1 CTC AAT TGA CAA TGA TCT 
  P3 
  
CGCT TAG GAT GAT CGG TG 
  
      
Vvu16S51-F 16S rRNA 
mostly Biotype 
1 CAA GTC GAG CGG CAG CA quantitative (27) 
Vvu16S221-R 
  
TCC TGA CGC GAG AGG CC 
  
Vvu16SA-P 
 
type A TGA TAG CTT CGG CTC AA 
  vu16SB-P 
 
type B CCC GTA GGC ATC ATG C 
  
      
HP1F allele 1 for capsule 
C/V,  
Biotype 1 
TTT GGG ATT TGA AAG GCT 
TG qualitative (41) 
HP1R 
  
GTG CCT TTG CGA ATT TTG 
AT 
  
HP2F allele 2 for capsule 
E/A  
Biotype 1 
TTC CAT CAA ACA TCG 
CAGA A 
  
HP2R 
  
CTT TTG TCC GGC TTC TAT 
CG 
  
      
F-viuB viuB,  siderophore 
C/V 
Biotype 1 
GGTTGGGCACTAAAGGCAG
ATATA qualitative (40) 
R-viuB 
  
CGGCAGTGGACTAATACGCA
GC 
  
      
PilF-F pilF, pilus type F 
C/V, 
Biotypes 1, 2, 
& 3 
GAT TGA CTA CGA YCC ACA 
CCG quantitative (85) 
PilF-R 
  
GRC GCG CTT GGG TGT AG 
  
PilF-P 
  
TGC TCA ACC TCG CTA AGT 
TGG AAA TCG ATA C 
  
      
vvC-F vcg 
C/V 
Biotype 1 
MMA AAC TCA TTG ARC 
AGT AAC GAA A quantitative (88) 
vvC-R 
  
AGC TGG ATC TAA KCC CAA 
TGC 
  
vcgC-P 
  
AAT TAA AGC CGT CAA GCC 
ACT TGA CTG TAA AGA A 
  1 Clinical or virulent strains 
2 
Environmental or avirulent strains 
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Capsular polysaccharide. Production of an extracellular capsular 
polysaccharide (CPS) is a key virulence factor for human and animal pathogens. 
Extracellular acidic polysaccharide capsule (CPS) is deemed as the most significant 
virulence determinant because CPS allows V. vulnificus evade host immune response by 
avoiding phagocytosis and complement mediated immunity (37, 68). CPS with 
lipopolysaccharide is thought to play an important role in septic shock formation by 
stimulating the expression of inflammation-associated cytokines (IL-6 and TNF-α) (89). 
The differentiation of capsular V. vulnificus from the non-capsular one can be done by 
the observation of colony morphology. While the presence of capsule gives opaque 
colonies, non-encapsulated strains display translucent colony morphology on media (90, 
91). Rosche et al. (92) indicated a third colony that seems to produce an intermediate 
level of CPS expression, suggesting that intermediate colony possesses opacity between 
translucent and opaque morphotypes and has a stable phenotype. Decreased expression 
of CPS highly correlates with the reversible conversion of opaque colonies to translucent 
colonial morphology. Again opaque colonies are more virulent than translucent strains. 
The amount of CPS in V. vulnificus strains is highly related to the degree of virulence in 
the animal models (91). Results from this study revealed that the CPS-mutant isolates 
generated by transposon mutation have an LD50 much higher than wild type strains 
possessing a polysaccharide capsule (91). CPS mutant strains, created as a consequence 
of constructed mutation or from naturally occurring phase variation, demonstrated 
decreased virulence activity in mice model (90, 93-95). Non-encapsulated strains are not 
protected from human defenses. Shinoda et al. (96) observed the susceptibility of non-
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encapsulated mutants to bactericidal effects of human serum. Translucent isolates 
showed an intermediate level of capsule production; whereas, opaque colonies resulted 
in an elevated level of expression of CPS during logarithmic growth and the amount of 
capsule was decreased during stationary phage. It was also observed that a significant 
amount of CPS was produced at 30°C relative to 37°C (97).  
Smith et al. (98) determined the functions of three gene clusters (Table 2) and 
four unidentifiable ORFs (open reading frames) involved in synthesis of CPS. Studies 
have shown that mutations in those genes reduce or remove virulence ability of 
pathogenic bacteria. Four genes in the wcv cluster (wcvA, wcvF, wcvI, and ORF4) were 
determined to be essential for synthesis of CPS in V. vulnificus by randomly inserting 
transposable DNA elements i.e. transposons into chromosomal DNA. When transposons 
were inserted into genes of interest, attenuation or a halt of expression occurred, thus 
showing that each of these genes of interest is crucial for CPS expression. Besides, 
another gene responsible for encoding an epimerase enzyme involved in capsule 
expression was also identified, and transposon insertion mutagenesis into this epimerase-
coding gene indicated that mutants lost the ability to produce a discernible CPS (99). 
Plasmid mediated insertion of ORF9 DNA, having 85% homology with an epimerase 
produced by V. cholerae O139, into the chromosome of an non-encapsulated, translucent 
strain of V. vulnificus, completely restored CPS synthesis and reduced the LD50 from 4.9 
× 10
7
 cells to only 9.7 cells (99). A group 1-like capsular polysaccharide operon for V. 
vulnificus was identified, and suggesting the function of the wza gene as an operon 
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essential for CPS synthesis in V. vulnificus. The wza gene is also a determinant for 
classification of Group I capsules (100). 
The assembly system of capsules also influences virulence. Whitfield et al. (101) 
identified four distinct capsule assembly systems in E. coli, based solely on genetic and 
biosynthesis products that have since been used for classification of CPS in bacterial 
pathogens into Groups I-IV. Fifteen CPS types were identified among 38 clinical and 
environmental V. vulnificus strains, however two different serologically and sugar 
moiety distinct types were synthesized only by the more virulent clinical strains. They 
were later identified as Group I and Group IV capsules from sequencing and 
experimental mutation analyses of chromosomal DNA (28). 
 
Iron uptake. Iron is essential for growth of microorganisms and plays an 
important role in bacterial virulence to human (102). In mammals, iron is intracellularly 
bound to lactoferrin (a form of transferrin protein) or as a cofactor in hemoglobin, and 
no free iron is available to invading bacteria so many pathogenic bacteria, including V. 
vulnificus, have developed various iron-scavenging mechanisms i.e. siderophores, 
hemophores and their receptors on the outer cell membrane as well as transferrin 
receptors in order to obtain iron from iron transport protein such as lactoferrin, and 
transferrin (103, 104). A recent publication from Skaar (104) proposes that “nutritional 
immunity” should be considered the first line of defense that literally starves bacterial 
pathogens of iron required for DNA replication needed for cell division and protection 
from oxidative stress. It has been shown that  
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Table 2. Gene clusters involved in synthesis of CPS in V. vulnificus 
Functional 
Gene Clusters 
Putative functions of CPS proteins 
Wcv Cluster  
wcvA Nucleotide-sugar epimerase (= an isomerase enzyme that catalyzes the rearrangement of 
–OH groups in biomolecules) 
wcvB Nucleotide sugar dehydrogenase 
wcvD Glycosyltransferase 
wcvE Glycosyltransferase 
wcvF Rhamnosyltransferase 
wcvG Glycosyltransferase 
wcvH Biosynthesis of activated monosaccharide precursors, confers serotype specificity 
wcvI Glycosyltransferase 
Rml Cluster  
rmlA Glucose-1-phosphate thymidylyl-transferase, L-rhamnose synthesis 
rmlD dTDP-4-keto-L-rhamnose reductase, L-rhamnose synthesis 
rmlC dTDP-6-deoxy-D-xylo-4-hexulose 3,5 epimerase, L-rhamnose synthesis 
Wzy Cluster  
wecA Undecaprenyl phosphate N-acetyl glucosamine 1-phosphate transferase. Initiates transfer 
of activated repeat unit precursors such as GlcNa-1-phosphate to a phosphate lipid 
carrier. 
wza, wzb, wzc Translocation proteins that export CPS to outer cell surface, required for surface 
expression of Group I CPS. Wza forms a multimeric channel complex in outer 
membrane for polymer export, wzc is an inner membrane tyrosine autokinase, and wzb is 
the cognate phosphatase to wzc. 
wzx O-antigen flippase that translocates repeat sugar units across the periplasm. Also has 
been described as a polysaccharide translocase. 
wzy Wy-Polymerase and production of O antigen specific to Group IV capsules. 
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V. vulnificus can acquire iron from transferrin, hemoglobin, met-hemoglobin, and 
hematin and this ability is associated with virulence (76, 105-110). Siderophores are low 
molecular weight iron binding complexes that can bind atomic iron with equal or greater 
affinity than a host’s iron sequestering transferrin or heme proteins. The presence of 
siderophore encoding genes (vuuA, venB, vvsA and vvsB) and their level of expression 
are correlated with degree of virulence of V. vulnificus (111-113). In addition to 
siderophore, Litwin et al. (111) showed that V. vulnificus is able to acquire non-
transferrin bound iron with the help of heme receptor called Hup A, and also suggested 
that non-transferrin-bound iron is believed to be necessary for initiation of growth. There 
is evidence that the more virulent clinical strains can survive for longer periods in human 
serum than environmental strains due to their ability to acquire iron. Different survival 
period was observed among environmental and clinical V. vulnificus genotypes in human 
serum in terms of the significance of iron uptake, suggesting that the environmental 
strains (E type) are less able to survive compared to more-virulent C type strain (114). 
Proteases and hemolysin/cytolysin secreted by V. vulnificus is believed to aid in iron 
uptake through the breakdown of heme-binding proteins (115, 116)  
Elevated iron in immune compromised and chronically ill individuals makes 
them more susceptible to V. vulnificus infection. In early studies of virulence, Wright et 
al. (117) determined that LD50 was much more reduced (from 10
6
 to 1 CPU) in iron 
treated mice compared to untreated host. Two hypotheses of how excess iron gives an 
advantage to V. vulnificus have been proposed: 1) Excessive amount of iron is thought to 
result in decreased phagocyte activity (118), 2) Iron can significantly enhance the 
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replication and growth rate of V. vulnificus, thus resulting in increased susceptibility of 
iron-overloaded host to infection (119). 
 
Pili. Attachment and colonization of host surface is important for host invasion 
by V. vulnificus because host cell contact is needed for cytotoxicity and virulence (113). 
Interaction of specific domain on a pilus with host cell surface receptor enables 
adherence of bacteria to host cells (120). In V. vulnificus strains, mutation of the pilA 
gene encoding pilin structural protein and pilD gene encoding for pre-pilin peptidase 
results in decreased adherence to epithelial cells and causes a slight reduction in 
virulence (31). Clinical strains of V. vulnificus collected from blood and wounds of 
infected individuals were found to have a higher number of pili per cell than 
environmental strains (121). The presence of pilus is obviously correlated with 
attachment, invasion of a host and virulence. 
 
Flagella. Motility enabled by the presence of flagella also influences virulence. 
Mutations of   genes flgC, encoding flagellar basal body, and flgE, encoding flagellar 
hook protein, resulted in defective motility, decreased attachment and cytotoxicity to 
HeLa cells that subsequently resulted in a decrease or loss of pathogenicity in V. 
vulnificus (32, 46). When flgC and flgE mutants were injected into mice to observe the 
effect of presence of flagella in virulence, the result showed that mutant strains had a 
higher LD50 as compared to that of wild-type strains. The decrease in motility is also 
believed to diminish adhesion to host cells, which consequently causes loss of secretion 
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of cytotoxin and virulence so therefore production of flagella is considered a required 
factor for virulence (32, 46).  It has also been suggested that in addition to their role in 
host cell adherence, flagella may serve as a type III secretion system for V. vulnificus 
toxins (32). 
 
Outer membrane proteins. Pathogenic bacteria utilize outer membrane surface 
proteins for adhesion to and invasion of a host. Fibronectin is thought to be the most 
important host matrix for cellular adherence by pathogens (122). A fibronectin-binding 
protein in V. vulnificus (ompU) was determined by Goo et al. (33) to be a predominant 
protein in the outer membrane. Significant reductions in binding capacity to fibronectin 
was observed for mutant ompU strains as compared to wild-type strains, suggesting that 
defects in interaction between ompU and fibronectin results in decreased adherence to 
host cells at the start infection. This study also observed significant decreases in 
adherence of mutant ompU strains to HEp-2 cells as well as loss of cytotoxicity with ten-
fold increases in LD50, suggesting that cell-to- cell contact is required for cytotoxicity 
(33). 
 
RtxA toxin. RtxA toxin has been identified as having an essential role in 
cytotoxicity of a broad range of pathogenic bacteria (123). In V. vulnificus its target 
activity is to depolymerize actin in host cells and its amino acid sequence and the 
organization of rtx gene cluster is highly similar (91% identical) to those in pathogenic 
strains of V. cholerae (124). Similar to the tests of virulence and CPS gene expression, 
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transposon mutagenesis attenuated expression of rtxCA and rtxBDE genes and decreased 
cytotoxicity toward INT-407 human intestinal epithelial cells (125). RtxA toxin produced 
by V. vulnificus is apparently only able to damage a host cell through cell-to-cell contact 
and therefore necessitates transfer to the outer cell membrane (113). Secretion of RtxA 
toxin is regulated by rtxE gene, on the rtxBDE operon. Transposon mutation of the rtxE 
gene eliminated the ability of V. vulnificus isolates to secrete RtxA toxin and resulted in 
decreased cytotoxicity (126).  
 
Hemolysin/cytolysin. In addition to siderophores and hemophores, V. vulnificus 
produces hemolysin/cytolysin (vvhA) toxin that facilitates iron acquisition by lyses of 
hemoglobin (109, 115). Purified vvhA has also been found to increase vascular 
permeability, skin damage, and death rate in mice (35, 43). Moreover, the inoculation of 
hemolysin (vvhA) into mouse epithelial cells resulted in skin damage similar to those 
resulted from infection of V. vulnificus (35). VvhA can also stimulate production of 
guanylate cyclase in the host, causing an increase in the amount of intracellular cyclic 
GMP, and consequently vasodilation (127, 128). VvhA also functions as a “pore forming 
protein” in cellular membranes (129). 
 
  Metalloprotease. V. vulnificus is able to secrete an extracellular protease (vvpE) 
possessing collagenase, elastase and zinc-dependent metalloprotease activity (44, 130). 
Inoculation of purified  vvpE  into mice caused dermal necrosis, edema and increased 
vascular permeability (131). However, vvpE mutant strains did not show any reduction 
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in cytotoxicity or virulence in mice compared to wild-type strains (132). The 
metalloprotease component of vvpE is apparently not essential for virulence in V. 
vulnificus because no differences were found LD50’s of mutant and wild type strains 
(133). Interestingly, an increase in the expression of vvhA (hemolysin-cytolysin) was 
observed in vvpE mutant strains suggesting that when the extracellular protease is 
absent, a greater amount of cytolysin is produced to sustain and even increase global 
virulence in V. vulnificus (133). 
 
Biofilm and V. vulnificus 
Due the nature of infections (i.e. septicemia and wound infections) the biofilm 
form in the life cycle of V. vulnificus has mostly been ignored. The few studies of 
biofilm formation by V. vulnificus have focused on the identification of proteins essential 
for biofilm development (pili, flagella, and outer membrane) (31, 46, 47, 134). 
Bacterial biofilm is a structured community of bacterial cells enclosed in a self-
produced polymeric  matrix and adherent to an inert or living surface (135). Biofilm is a 
protective mode of growth of diverse range of organisms in both Archaea and Bacteria 
lineages in order to survive within hostile environments and disperse to nutrient rich 
environments for the establishment of new biofilm architectures (136). Bacteria in a 
biofilm exhibits distinct properties from their planktonic form (137). In general, biofilm 
forming microorganisms inherently represent more resistance to antimicrobials than 
planktonic counterparts (135, 137). Biofilm provides benefits to biofilm-forming cells in 
diverse harsh environments. Protections from desiccation, biocides, antimicrobial 
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treatments, host defenses, surfactants, and ultraviolet radiation are a few advantages of 
biofilm matrix integrity to colonized cells (138-140). Biofilm matrix also provides a 
suitable environment which facilitates the horizontal gene transfer between 
microorganisms, the sequestration of dissolved organic matters into the biofilm by the 
production of external digestive system, and allowing the use of those nutrients as 
energy sources (138). 
The first step to form a biofilm is the process of bacterial attachment to inert or 
living surfaces (Fig. 1). The adhesion to inert surfaces is usually accomplished by 
nonspecific interactions (electrostatic, hydrophobic), while attachment to biotic surfaces 
i.e. living tissues is dictated by specific molecules such as lectin and other ligands (139). 
Microorganisms have to reach to an available surface in close proximity by either 
randomly flow of water or chemotaxis in order to loosely bind to surfaces, then 
irreversible binding takes place between surfaces and attached microbial cells by the 
production of exopolysaccharide (137). Pili and flagella are also involved in the first 
stages of biofilm formation. Flagella-mediated motility and the presence of pili favor the 
initial steps of biofilm formation and play a key role in biofilm formation in vibrios (51). 
After the irreversible attachment of microbial cells to surfaces, biofilm matures by 
proliferation and generation of extracellular dynamic polymeric matrix enveloping the 
attached microbial cells which are optimally structured to exploit the available nutrients 
(141, 142). Main matrix composition of a biofilm is comprised of microbial cells, water, 
exopolysaccharides and secreted /released extracellular products (142, 143). The matrix 
of biofilm is known as extracellular polymeric substance (EPS) which mediates 
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aggregation of the cells in close proximity to facilitate the complex interactions between 
bacterial cells and this EPS is also involved in mechanical stability and adhesion of 
individual cells in biofilm, thus facilitating the formation of multilayered architectural 
structure of biofilm (138, 141, 143). After maturation process reaches a critical mass, the 
dispersal of biofilm cells starts, in which the generated planktonic microorganisms 
escape the biofilm and disperse to new nutrient-rich environments for the establishment 
of new biofilm architectures (137).  
 
 
Figure 1: The five stages of biofilm development (144). Step1. reversible attachment; step2. irreversible 
attachment; step3. and step 4. maturation process; and step 5. dispersal. 
 
 
Although the composition of biofilm matrix largely depends on intrinsic and 
extrinsic factors (142), in vitro experiments demonstrated that biofilm matrix generally 
consists of exopolysaccharides (EPS0 (145, 146),  structural proteins (138), extracellular 
enzymes (147, 148) (145, 148), extracellular DNA (146), lipids (149), and water (150). 
The combination of intrinsic and extrinsic factors generate a dynamic heterogeneous 
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microenvironment for biofilm-forming cells (143). EPS makes up an important 
proportion of matrix framework and is responsible for the attachment to various surfaces 
by its cohesive and adhesive property (138, 142). The mechanical stability and formation 
of biofilm architecture are provided mostly by the production of EPS (138), thus 
considered main structural component of biofilm matrix. Mutants defective in the 
production of EPS were disabled to form mature biofilms (47, 151). EPS are also the 
most major component of vibrio biofilms (51).  
There are also several kinds of structural and enzymatic proteins involved in 
biofilm formation. The amount of protein in biofilm can remarkably differ between 
different biofilms. For example, the largest proportion (75%) of the Pseudomonas putita 
biofilm is comprised of proteins (152) although proteins typically make up 1-2% of most 
biofilm matrices (142). Structural proteins are responsible for the structural integrity and 
stability within biofilm (142). Accumulation-associated protein (Aap) in Staphylococcus 
epidermis is known to play a role in the establishment of intercellular adhesion (153). 
Additionally, Borlee et al. (154) identified a structural protein necessary for the 
contribution of structural integrity by exopolysaccharide cross-linking in P. aeruginosa 
biofilm.  
There are several extracellular enzymes present in a mature biofilm. Various 
enzymes in biofilm are involved in the degradation of biopolymers and the utilization of 
other organic particles embedded into biofilms for carbon and energy source and some 
are responsible for virulence factors in medical biofilms (138). Extracellular DNA has 
also been considered as integral part of biofilm matrix (145, 155, 156) and serves as an 
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intercellular connector and is involved in stabilization of P. aeruginosa biofilms (157). It 
has been hypothesized that DNA contributes to the matrix network stability by the 
interaction of oppositely charged-matrix molecules (141, 156) .  
It has been proposed that biofilm formation is a selective survival strategy of 
prokaryotic organisms to maintain their survival in harsh conditions, thereby facilitating 
the complex interactions, found only to be possible in close proximity between 
individual cells, and provides a suitable environment to communicate with each other by 
signaling pathways (136). Biofilm formation enables a microbial community capable of 
communicating each other via chemical signals called quorum sensing so it is one of the 
important factors for development of biofilm.  
Physical and chemical variables such as temperature, pH, salinity, and iron 
concentration play important roles for the development of biofilms. Diaz Villanueva et 
al. (158) evaluated the interactive effects of temperature with respect to nutrient 
availability on biofilm development, hypothesizing that an increase in temperature 
would play more important role during the early stages of biofilm formation when cells 
in a thinner biofilm can be better exposed to nutrients. Results from this study also 
predicted that if the nutrients are the limiting factor for growth, temperature will show a 
greater effect on biofilms at higher nutrient levels. In order words, when nutrient 
availability regulates the biomass of mature biofilm, biofilm formation at higher 
temperature is faster. Townsley and Yildiz (159) tested biofilm formation by V. cholerae 
and found that biofilms produced at low temperatures (15°C and 25°C), like those 
experienced in the aquatic habitat, had increased biomass and thickness and were more 
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structured compared with those formed at 37°C. Another study (160) determined that V. 
cholerae produced slightly higher biofilm even at 30°C compared to 37°C. Di 
Bonaventura et al. (161) examined the effects of temperature and pH on biofilm 
development of 51 Stenotrophomonas maltophilia clinical isolates. They observed 
higher biofilm formation at 32°C than at either 18°C or at 37°C, and the amount of 
biofilm produced was significantly higher at pH 7.5 and pH 8.5 than at pH 5.5. This 
study also indicated that strain-to-strain differentiations, regardless of environmental 
factors, have a marked effect on the biofilm development of S. maltophilia. While most 
clinical strains of S. maltophilia produced biofilms, 2% of the clinical strains did not 
form biofilm under the same conditions. Seemingly, not all clinical strains have the 
potential to form biofilm, and environmental parameters and host factors are also 
important to enable the individual strains to form biofilm. V. cholerae produces biofilm 
for protection in the presence of bile acids (162) that normally restrict bacterial growth 
in the small intestine (163). Havasi et al. (164) found that one of the factors affecting the 
development of biofilm is sodium chloride, which might have a functional effect on 
biofilm formation and quorum sensing of P. aeruginosa. Iron regulates biofilm 
formation by several human pathogens (157, 165-167). S. aureus, that forms biofilms in 
chronic wounds (168) and is one of the most frequently isolated pathogens associated 
with nosocomial sepsis (169), produces more biofilm with increasing iron concentration, 
up to 200 µM (165). In some bacterial species, the concentration of iron is inversely 
correlated with the development of biofilm. Some studies have suggested that the 
increase in iron concentration causes a reduction in the amount of P. aeruginosa biofilm 
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(157, 170, 171). Other experiments with the cultures of P. aeruginosa have also shown 
that the increased concentration of iron, up to 100 μM FeCl3 in polystyrene microtiter 
trays, suppressed the development of biofilm and subpopulation with decreased resistant 
toward antimicrobial compounds; conversely low iron concentration media (5 μM FeCl3) 
favored the development of P. aeruginosa biofilm and of the resistance to antimicrobial 
compounds (157).  
Swarming behavior in pathogenic bacteria has been correlated with biofilm 
formation in other pathogenic bacteria but has not yet been investigated in V. vulnificus.  
Thus far swarming behavior V. vulnificus has been tested for correlation with only a 
single virulence factor, hemolysin-cytolysin (vvh) production, and was determined to 
have either no or a down-regulatory effect (172). However, swarming behavior as well 
as production of vulnibactin, a siderophore, is both downregulated by the LuxS quorum 
sensing system and Fur (ferric uptake regulator) in V. vulnificus in the presence of iron 
rich media (173). Interestingly, Kim et al. (172) observed that swarming behavior was 
significantly increased when V. vulnificus was grown on softer 0.3% agar rather than the 
normal 0.5%. The semi-solid consistency of biofilms may be conducive to swarming in 
V. vulnificus. Swarming and quorum sensing may also be important strategies for host 
infection of wounds. If virulent clinical strains preferentially live attached to flocs of 
biofilm and extracellular polymeric substances in the water column, then the likelihood 
of wound infection encounter and successful adhesion may be higher than that for 
environmental strains living planktonically. 
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Adaptation of vibrios to fluctuating environmental factors is also dramatically 
important for their survival and colonization, suggesting that biofilm forming capacity is 
a fundamental factor for their survival in aquatic ecosystem (51). Studies with the 
sample of cholera patients revealed that biofilm-like aggregates were observed in those 
patients in addition to planktonic forms of V. cholerae (49). The biofilm forming ability 
of V. cholerae was examined under in vivo and in vitro conditions (49, 174, 175), and 
suggested that V. cholerae has the ability to form biofilm in both host and aquatic 
environments. Unlike V. cholerae host infections, V. vulnificus are not primarily 
restricted to the small intestine but instead occur in blood, skin, muscle, and other 
tissues, thus biofilm-forming ability of V. vulnificus in host phase has not yet been 
reported and/or rarely been investigated in clinical research due to the nature of 
infection. In vitro experiments reveal that V. vulnificus has the ability to develop 
biofilms (31, 45-48), so biofilm formation might be an important strategy for the 
survival of virulent strains versus less virulent environmental strains in marine 
environments until it can infect the host.  
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CHAPTER III  
 
QUANTITATIVE PCR ENUMERATION OF VCGC AND 16S RRNA TYPE A/B 
GENES AS VIRULENCE INDICATORS FOR ENVIRONMENTAL AND 
CLINICAL STRAINS OF VIBRIO VULNIFICUS IN GALVESTON BAY 
OYSTERS 
Overview 
Oysters from a reef in Galveston Bay, TX, USA were screened for more virulent 
clinical versus less virulent environmental strains using a combination of quantitative 
PCR assays for the virulence correlating gene (clinical variant, vcgC) and 16S rRNA 
type A/B (type A = environmental, type B = clinical). The combination of vcgC and 16S 
rRNA type B loci to determine clinical type strains was suitable as indicated by the 
strong correlation (R
2
=0.98, p<0.001) between these gene counts over time and their 
relative proportion (up to 93.8% and 94.3%, respectively) to vvhA genes used to quantify 
all strains of V. vulnificus. A strong seasonal shift of V. vulnificus strain types was 
observed. Environmental strains (16S rRNA type A) predominated from April to mid-
June as salinities increased from 22 to 27 PSU and temperatures rose 20 to 28°C with 
peak gene quantities of 16,812±56 CFU/g. As temperatures increased to ≥30°C from 
mid-June to September and salinities rose above 27 PSU, clinical strains (16S rRNA 
type B; vcgC) predominated with peak quantities 31,868±287 and 32,360±178 CFU/g, 
respectively.  
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Introduction 
 
V. vulnificus is a gram-negative, halophilic, autochthonous pathogen found in 
estuarine waters worldwide (176). Human infection typically occurs through ingestion of 
raw or undercooked seafood (177) but can also occur by contamination of wounds (13). 
V. vulnificus can cause gastroenteritis, necrotizing wound infections, and septicemia and 
is the leading cause of foodborne deaths in the USA (12). Although rare, V. vulnificus 
infections can be life threatening in predisposed individuals who have high serum iron 
levels and immune deficiencies (176). Death can occur within 24 hr after contact and 
mortality rates are greater than 50% in septicemic patients (176). 
There are three known biotypes of V. vulnificus. Biotype 1 primarily infects 
humans, biotype 2 primarily infects eels, and biotype 3 is a hybrid of types 1 and 2 (12). 
Studies of V. vulnificus biotype 1 (hereafter referred to as simply V. vulnificus) have 
shown that there are degrees of pathogenicity or virulence. Historically, the more 
virulent strains were isolated from hospital patients and became known as ‘clinical’ 
strains whereas less virulent strains were isolated from seawater, oysters, fish, and other 
marine surfaces and became known as ‘environmental’ strains (23, 24). One of the first 
studies (23) to observe differences in virulence of clinical versus environmental strains 
used iron-overloaded mice and found that to achieve the same magnitude of infection as 
clinically isolated strains, environmentally isolated strains required a 350-fold higher 
inoculum. Since then focus has been on determining the variety of factors contributing to 
virulence. These include the extracellular capsule polysaccharide, endotoxins, 
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hemolysin/cytolysin, lipase, lecithinase, proteases, and collagenase as well as 
siderophores, pili, and flagella (37, 86, 97, 100, 178-180).  
Bacterial genotyping studies have determined several polymorphic loci within 
the V. vulnificus genome that are indicative of clinical (C) versus environmental (E) 
strains.  These loci include the virulence-correlated gene vcg (181, 182), 16S rRNA (25, 
183), the siderophore-encoding viuB (vulnibactin) gene (40), and the capsular 
polysaccharide (CPS) operon (24). Several studies have used vcg to distinguish between 
clinical and environmental strains (39, 182, 184). Vcg has two sequence variants, vcgC 
and vcgE. Rosche (39) consistently detected the vcgC variant in clinical isolates (90%) 
whereas ‘vcgE’ had a detection rate of 87% in environmental isolates. Another study 
however observed lower detection rates of vcgC (41%) and vcgE 59% (41). For 16S 
rRNA differentiation, sequence type B is associated with clinical strains and type A with 
environmental strains, however some environmental strains (mostly from oysters) have 
been found to possess both type B and type A sequences (12) and some type A strains 
have been isolated from hospital patients who recovered from infection (25). In a study 
of Louisiana oysters (41), 16S rRNA type B strains were detected 76% of the time in 
clinical isolates and type A only 15% of the time in environmental isolates. Greater 
agreement was observed by Nilsson et al. (25) who examined clinical isolates from 
patient fatalities (94% type B), patient recoveries (50% type B), and environmental 
strains from oysters or seawater (94% type A). The viuB gene, having one genotype, 
appears to be less specific with a 100% detection rate in clinical isolates but a 24% 
detection rate in environmental isolates (40). The CPS operon also does not differentiate 
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clinical versus environmental V. vulnificus with great accuracy. The CPS operon has two 
genotypes, 1 and 2. Genotype 1 matched clinical isolates 64% of the time and genotype 
2 matched environmental isolates only 27% of the time (41). Han et al. (41) compared 
the accuracy of various combinations of loci. Regardless of whether two or three loci 
were used, combinations including vcgC and 16S rRNA type B gave higher percentages 
of clinical isolates (73.6 to 89.7%) while combinations including CPS and viuB gave 
lower percentages (56.2 to 66.5%). Although no single locus is 100% indicative of 
clinical versus environment strains, the virulence correlated gene vcgC and 16S rRNA 
type A/B appear to be the most promising thus far. 
In this study we used quantitative PCR (qPCR) assays for the vcgC and 16S 
rRNA type A/B genes as well as the vvhA (V. vulnificus-specific hemolysin/cytolysin) 
gene to determine the occurrence and potential seasonality of clinical versus 
environmental strains of V. vulnificus in oysters. Thus far, genotyping studies of V. 
vulnificus virulence factors have primarily characterized clinical and environmental 
isolate cultures with traditional PCR. This study demonstrates the application of qPCR to 
oysters in their natural state. Quantitative PCR (qPCR) allows for rapid detection of 
targeted sequences without the requirement of time-intensive isolation and has been used 
to examine V. vulnificus in the environment and in experimental settings (78, 185, 186). 
Moreover qPCR can quantify cells that might be excluded during isolation methods. 
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Materials and methods 
Sample collection and processing. Oyster samples harvested in 2009 and 2010 
from a reef located in the west bay of Galveston Bay called ‘Sammy’s Reef’ (lat 
29.254840
∘
 lon -94.918749
∘
) were homogenized with a Waring blender (Fisher 
Scientific) and then diluted 1:10 (vol:vol) with alkaline peptone water (APW), incubated 
at 35°C with shaking at 100 rpm for 24 hours. A 1 ml aliquot was frozen in 2 ml tubes 
for later DNA extraction. 
 
DNA extraction. Frozen samples were thawed and centrifuged in an AccuSpin 
Micro R Centrifuge (Fisher Scientific) at 4°C 10,000 rpm for 10 minutes. The 
supernatant was removed and 3% CTAB (cetyltrimethylammonium bromide, 500 μl) 
was added. The tubes were incubated for an hour in a water bath at 60°C. During 
incubation time, the tubes were vortexed every 10 minutes to facilitate the lysis of 
bacterial cell walls. Next, 500 μL of chilled 24:1 choroform:isoamyl alcohol was added 
and vortexed on high for a good emulsion in order to dissolve the cell membrane of 
bacteria by binding lipids and proteins. The emulsions were centrifuged for 10 minutes 
at 10,000 rpm (4°C).  At the end of the centrifugation a top aqueous layer containing 
DNA, a middle interphase with cellular debris, and a lower organic phase were visible. 
Lipids and proteins are non-aqueous compound and DNA/RNA is aqueous compound so 
DNA was in the aqueous phase while cell debris and organic phase were in the middle 
and lower organic phases. The aqueous phase was carefully transferred into a new 2ml 
Eppendorf tube and 2/3 volume of ice-cold isopropanol was added. Tubes were gently 
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tipped back and forward a few times to precipitate the DNA, and then stored at -20°C 
overnight. After overnight precipitation, the tubes were centrifuged 4°C 10,000 rpm for 
10 minutes, the supernatant (isopropyl) was decanted and the tubes were air dried for 2 
hr. Ice-cold ethanol (80%; 200 μl) was added to remove salts. The ethanol was decanted 
and the precipitated DNA was allowed to dry for 1-2 hours at room temperature with the 
tubes tipped downward and the caps off.  DNA was rehydrated overnight at room 
temperature with a buffer containing 10 mM Tris, 10 mM NaCl, and 0.5 mM EDTA. 
DNA extracts were stored at -20°C. 
 
Measurement of DNA concentration. The concentration of extracted DNA (ng/ 
μL) was measured spectrophotometrically (NanoDrop ND-1000). The ratio of 
absorbance at 260 nm and 280 nm was used to access the purity of DNA.  
 
Multilocus qPCR assays. Four primers sets were used to quantify the virulence 
factor genes vvhA, 16S types A and B and vcgC. All reactions were performed in 
duplicate. 
VvhA, the cytolysin-hemolysin gene that is specific to all V. vulnificus, was 
quantified in a SmartCycler (Cepheid) using gene specific primers and a probe labeled at 
the 5’ end with Texas Red and at the 3’ end with BHQ1 (Table 3). Thermal cycling was 
performed using a two-step PCR protocol: 50°C for 2 min, 95°C for 10 min and 40 
cycles of 95°C for 15 s and 60°C for 1 min. The reaction mixture (20 μl) consisted of 1 
μl template DNA (different concentrations), 1×PCR Buffer, 1 μM each primer, 250 nM 
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probe, 200 nM dNTPs, 2.5 mM MgCl2, 1×BSA (bovine serum albumin), and 1 U Taq 
DNA polymerase (Roche). PCR positive control for qPCR and construction of standard 
curve was clinical strain 9038-96 obtained from the U.S. FDA Gulf Coast Seafood 
Laboratory. 
16S A and 16SB rRNA was quantified with a SmartCycler (Cepheid) using gene 
specific primers (Table 3) and Sybr Green intercalating dye. The reaction mixture (20 μl) 
consisted of 2 μl DNA template (different concentrations), 1 μM each primer, 2.5 mM 
MgCl2, 1×BSA and 10 μl of IQ Sybr Green Supermix (BioRad) that contains Taq DNA 
polymerase, and dNTPs. Thermal cycling was performed using a three-step PCR 
protocol: 45 cycles of 95°C for 20 s, annealing at 60°C for 30 s, and extension at 72°C 
for 25 s. The cycle threshold (CT) values were obtained when the fluorescence readings 
crossed a threshold of 30 units. Melt curve analysis was conducted from 60°C to 94°C at 
increments of 0.2°C per second. PCR positive controls for qPCR and construction of 
standard curves were clinical strain BUF7211 (type B) and environmental strain 98-640 
(type A) obtained from the U.S. FDA Gulf Coast Seafood Laboratory. 
  VcgC (clinical variant) was quantified with a SmartCycler (Cepheid) using gene 
specific primers (Table 3) and Sybr Green intercalating dye. The reaction mixture (20 μl) 
consisted of 2 μl DNA template (different concentrations), 1 μM each primer, 2.5 mM 
MgCl2, 1×BSA and 10 μl of IQ Sybr Green Supermix (BioRad) that contains Taq DNA 
polymerase, and dNTPs. Thermal cycling was performed using a three-step PCR 
protocol: 45 cycles of 95°C for 20 s, annealing at 60°C for 30 s, and extension at 72°C 
for 25 s. The cycle threshold (CT) values were obtained when the fluorescence readings 
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crossed a threshold of 30 units. Melt curve analysis was conducted from 60°C to 94°C at 
increments of 0.2°C per second. PCR positive control for qPCR and construction of 
standard curve was clinical strain BUF7211 obtained from the U.S. FDA Gulf Coast 
Seafood Laboratory. 
 Standard curves were created in the Smart Cycler according to manufacturer 
instructions with the same primer sets and probes or intercalating dye using genomic 
DNA extracted from graduated concentrations (10
1
, 10
2
, 10
3
, 10
4
, 10
5
, 10
6
, and 10
7
) of 
control V. vulnificus strains containing the target gene. Counts (CFU) of V. vulnificus 
were generated by the standard curve and any dilutions were figured into the back 
calculation to the original DNA extraction volume. Final CFU/g was determined using 
the weight of the oyster tissue that was extracted.   
 
Statistical Analysis. Regression analyses (p>0.05) and two sample T-test 
(p>0.05) were conducted with STATA 13.1 (StataCorp). 
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Table 3. Primers and probes used to quantify virulence factor genes in V. vulnificus. 
Target Gene 
Strain 
Specificity 
Primer 
or Probe 
         Primer Sequence (5'-3') References 
V. vulnificus-
specific 
hemolysin  
all strains 
VVH-F 
TGTTTATGGTGAGAACGGTGAC
A 
(78) VVH-R 
TTCTTTATCTAGGCCCCAAACTT
G 
VVH-
probe  
Texas Red-CCGTTAACCGAACCA 
CCCGCAA-BHQ1 
16S rRNA 
type A-
environmenta
l 
VVAF1 CATGATAGCTTCGGCTCAA 
(186) 
VVAR1 CAGCACTCCTTCCACCATCAC 
type B-
clinical 
VVBF1 GCCTACGGGCCAAAGAGG 
VVBR1 GTCGCCTCTGCGTCCAC 
vcgC clinical 
VCGF3 CGCCTTTGTCAGTGTTGCA 
(184) 
VCGB3 TAACGCGAGTAGTGAGCCG 
 
 
 
Results 
 
Temperatures (Fig. 2) at Sammy’s Reef did not rise above 20°C until 4/13/10 
when they gradually increased to 31.5°C on 8/16/10. After 8/24/10 temperatures began 
to gradually decrease to below 20°C and then fell to 9°C on 12/13/10. Salinity (Fig. 1) 
hovered around 20 PSU until 4/13/10 and then gradually increased to 31 PSU on 6/8/10. 
There was a drop in salinity to 23-27 PSU in August with a spike in salinity on 9/4/10 
and then gradual decrease to 15 PSU on 11/9/10 then increased steadily again to 32 PSU 
on 12/13/10. 
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Figure 2. Temperature (°C) and salinity (PSU) in seawater at Sammy’s Reef 
between 12/8/09 and 12/8/10. 
 
 
VvhA (cytolysin-hemolysin) genes (expressed as CFU/g), used to quantify all 
strains of V. vulnificus, were undetectable from 12/8/09 to 4/13/10 with the exception of 
2/9/10 where levels were 280±8 CFU/g oyster homogenate and 3/2/10 with 200±4 
CFU/g (Fig. 3a) which were preceded by unusually warmer temperatures (22 and 23°C). 
VvhA counts rose steadily from 3,100±21 to 34,153±110 CFU/g between 4/13/10 and 
8/31/10, with the rise in seawater temperature from 20 to ≥30°C. Between 9/14/10 and 
11/16/10 vvhA counts decreased gradually from 32,249±132 to 3,947±27 CFU/g with the 
decrease in seawater temperature and were undetectable after 12/6/10 when temperatures 
dropped below 20°C.  
 16S rRNA type A genes, indicative of less virulent ‘environmental’ strains, were 
first detected on 2/9/10 and 3/2/10 (240±9 and 196±11 CFU/g, respectively) but then 
remained undetectable until 4/13/10 (1,008±22 CFU/g) when temperatures rose above 
°C
 
P
S
U
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20°C and peaked on 6/15/10 with 16,812±56 CFU/g (Fig. 3b). After 6/15/10, as 
temperatures rose to ≥30°C quantities decreased gradually to 2,008±31 CFU/g on 
8/16/10 and remained at <2,000±27 CFU/g until 11/16/10 and were non-detectable by 
December when temperatures dropped below 20°C.  
 16S rRNA type B genes, indicative of the more virulent ‘clinical’ strains were 
undetectable until 4/13/10 (2,013±43 CFU/g), but then increased steadily to 31,868±287 
CFU/g on 8/16/10 as temperatures reached ≥30°C and then decreased gradually to 
3,301±55 CFU/g on 11/16/10 as temperatures dropped below 20°C (Fig. 3b). 
VcgC, clinical variant, increased gradually from 1,750±29 CFU/g on 4/13/10 to 
32,360±178 CFU/g on 8/31/10 then decreased gradually to 2,850±23 CFU/g by 11/16/10 
(Fig. 3c) and were non-detectable by December when temperatures dropped below 20°C. 
Examination of proportion of 16S rRNA type A genes to the total V. vulnificus 
pool (i.e. % of vvhA genes) in oysters found that 16S rRNA type A genes could account 
for 32.5 to 74.5% of V. vulnificus from 4/13/10 to 6/28/10 (Fig 4a). After 6/28/10 
proportion of 16S rRNA type A genes out of vvhA genes decreased to below 10%. 
Proportion of 16S rRNA type B genes to vvhA genes ranged from 79.8 to 93.8% between 
8/3/10 to 11/16/10 (Fig. 4b). VcgC genes followed a similar distribution to 16S rRNA 
type B genes accounting for a high percentage of detected V. vulnificus (i.e. % of vvhA 
genes) ranging from 72.2 to 94.3% between 8/3/10 and 11/16/10 (Fig. 4c). This 
similarity was confirmed by a strong correlation (R
2
=0.98, p<0.001) of vcgC to 16S 
rRNA type B gene counts (Fig. 5). 
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Discussion 
We observed strong seasonality for 16S type B and vcgC genes indicative of 
clinical strains of V. vulnificus as well as for the 16S type A gene indicative of 
environmental strains in Sammy’s Reef oysters. Environmental strains (i.e. 16S type A) 
dominated the pool of V. vulnificus from April to June as water temperatures gradually 
rose from 18 to 28°C and salinities increased from 22 to 27 PSU but were then 
succeeded by clinical strains (i.e. 16S rRNA type B and vcgC) from July through 
September when water temperatures were sustained at 30°C or above and salinities rose 
above 27 PSU. These results are in relative good agreement with Lin and Schwarz (53) 
who examined V. vulnificus isolates from Galveston Bay, TX, USA seawater over a 13 
month period and found that 16S rRNA type A isolates were predominant from February 
to June as temperatures gradually rose to just above 20°C but then dropped dramatically 
when temperatures rose to between 25 and 30°C. 16S rRNA type B isolates 
predominated from July to October as temperatures rose to 30°C. Both 16S type A and B 
strains decreased rapidly with the onset of autumnal cold fronts and were non-detectable 
by  
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Figure 3. CFU/g a) vvhA, b) 16S rRNA types A and B, and c) vcgC in 
Sammy’s Reef oysters between 12/8/09 and 12/8/10. 
b 
c 
a 
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Figure 4. Proportion (%) of genes a) 16S rRNA type A, b) 16S rRNA type B, and c) vcgC out of 
the total V. vulnificus pool as determined by quantification of vvhA genes. 
 
 
a 
b 
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Figure 5. Correlation of 16S rRNA type B with vcgC CFU/g. R
2
=0.98, p<0.001. 
 
 
 
December. However, unlike the study by Lin and Schwarz (53) who isolated only 16S 
rRNA type A strains from February to May, we were able to detect both 16S rRNA type 
strains from April to December regardless of temperature or salinity. The difference was 
the quantities of one type to the other. In other words when 16S rRNA type A quantities 
were high, type B quantities were low and vice versa. This is likely a difference between 
occurrences of 16S rRNA types in seawater versus oysters that has been observed by 
other studies (182, 186).  
Han et al. (41), characterized clinical versus environmental V. vulnificus isolates 
from Louisiana oysters using traditional PCR assays for 16s rRNA type A versus type B, 
and vcgC (clinical variant) versus vcgE (environmental variant). Similar to our findings, 
both 16S rRNA types could be isolated from oysters throughout the sampling period 
from April to September. A seasonal trend in predominance of one type versus the other 
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was also observed. 16S rRNA type B isolates increased in relative number in warmer 
months (July to September) 16S rRNA type A isolates were highest in relative number 
in cooler months (April to June). The same trend was observed for vcgC versus vcgE 
genes. Numbers of isolates having the clinical variant of vcg (vcgC) were predominant in 
July to September whereas the environmental variant of vcg (vcgE) was more prevalent 
from April to June. Lin and Schwarz (53) suggested that the difference in seasonal 
occurrence of 16S rRNA type A versus type B strains may be due the viability of each 
strain to be resuscitated from a ‘viable but not culturable’ state after extended periods of 
cold winter temperature. It would appear that the 16S rRNA type A strains have the 
ability to resuscitate sooner during cooler temperatures (around 10°C) and lower 
salinities (below 10 PSU) while 16S rRNA type B resuscitate only when temperatures 
reach 20°C and above and salinities rise to above 20 PSU. This seasonal difference is 
important for harvesting of oysters. Not only are total numbers of V. vulnificus lower in 
cooler months, environmental strains predominate thus lessening the likelihood of 
infection. However, some oyster reefs are harvested in warmer months. The 
predominance of clinical strains increases the likelihood of infection even if total 
numbers of V. vulnificus are low because fewer cells are required for infection due to 
greater virulence.  
 We observed a strong correlation of 16S rRNA type B and vcgC genes in this 
study (R
2
=0.98; p<0.001; Fig. 5) as did Han et al. (41) (R
2
=0.99; p<0.001).  Han et al. 
(41) also examined other virulence factors such as allele type (clinical versus 
environmental for the capsular polysaccharide operon) and prevalence of the viuB 
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(siderophore encoding) gene as an indicator of clinical strains. Neither of these factors 
showed a strong correlation to occurrence of vcgC (R
2
=0.68, p=0.023 and 0.48, p=0.124, 
respectively) or to 16S rRNA type B (R
2
=0.68, p=0.043 and 0.45, p=0.139, 
respectively). Conversely, other researchers have proposed that 16S rRNA type may not 
be suitable for distinguishing clinical versus environmental strains. Gordon et al. (186) 
found that some environmentally isolated strains from oysters possessed both 16S rRNA 
gene types (A and B) whereas clinically isolated strains only possessed 16S rRNA type 
B genes. The overlap of 16S rRNA types in oysters determined in our study may be 
explained by presence of strains possessing both types (AB). Indeed, between 4/13/10 
and 6/7/10 the occurrence of type B genes was significantly higher (t-test, p = 0.000) 
than vcgC genes and distribution of the two had low correlation (R
2
=0.37; p=0.105). 
This may be explained by a preponderance of type AB strains, but we did not confirm 
this with isolate cultures. However as water temperatures rose to 30°C and above the 
correlation of vcgC and 16S rRNA type B genes was strongest (R
2
=0.99; p<0.001).  
Data on the correlation of genotype with in vivo testing of virulence are limited 
but are still useful in confirming the suitability of the vcgC and 16S rRNA type A/B loci 
to differentiate between clinical and environmental strains. Thiaville et al. (26) who 
examined the relationship of genotype to virulence in subcutaneously inoculated, iron 
dextran-treated mice found that 16S type A and AB strains had significantly lower 
incidence of skin and liver infection whereas type B had significantly higher incidence. 
Moreover, death rate was significantly higher for type B and AB strains than type A. 
This study also found that incidence and magnitude of skin infections was not different 
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for vcgE and vcgC genotypes however vcgC strain-infected mice had a significantly 
rates of systemic infection and death. Nilsson et al. (25) also observed differences of 
virulence in hospital patients. Isolates from patients who died were consistently type B 
(94%) but isolates from patients who recovered were 50% type B and 50% type A. 
Although there appears to be degrees of virulence within 16S rRNA type B, the use of 
assays for 16s rRNA A/B to differentiate clinical versus environmental strains are still 
useful in understanding the ecology of V. vulnificus.  
The results of our study confirm that are seasonal shifts in the virulence of the V. 
vulnificus population in oysters as demonstrated by the dominance of less virulent 
environmental strains in cooler months and more virulent clinical strains in warmer 
months. We found that the combination of vcgC and 16S rRNA A/B loci to be highly 
suitable differentiation of these strains.  A comparison of 16S rRNA type A+B gene 
counts to vvhA gene counts (i.e. total V. vulnificus) gave an 83 to 102% agreement 
indicating that most of the V. vulnificus pool had been detected by qPCR. A similar 
comparison of vcgC gene counts to vvhA gene counts gave a 55 to 95% coverage with 
the majority being >80%. However, the caveat of qPCR is that it also detects dead cells 
so that the data may not a true representation of the viable population. The combined 
application of these qPCR assays to rapidly screen oysters and other seafood for more 
virulent clinical strains of V. vulnificus will eliminate the need for lengthy isolation 
methods. 
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CHAPTER IV 
 
SELECTIVE ENRICHMENT FOR CLINICAL STRAINS OF 
VIBRIO VULNIFICUS 
Overview 
Traditional enrichment and maintenance media for V. vulnificus were tested for 
selective preference for clinical or environmental strains. In the laboratory, Alkaline 
Peptone Water (APW) and Brain Heart Infusion Broth (BHIB), with adjusted salinity to 
that of APW, were inoculated with equal concentrations of clinical and environmental 
strains and incubated for 20 hr at 35°C. BHIB selected for clinical strains (85%) as 
indicated by percentage of vcgC to vvhA genes, enumerated with quantitative PCR. In 
APW, the ratio of clinical to environmental strains was roughly equal. Enrichments of 
seawater with BHIB, APW, and Luria Bertani broth (LB) resulted in higher % clinical 
strains in BHIB but not in APW or LB, in most samples. However seasonal differences 
in predominance of clinical or environmental strains in the seawater samples influenced 
the enrichment process. The selective preference of the BHIB10 medium for clinical 
strains indicates that iron plays an important role in the infection of the human host.  
 
Introduction 
Life-threatening, halophilic, gram-negative marine bacterium Vibrio vulnificus 
was first isolated by the Centers for Disease Control (CDC) in 1964 (68), since then, 
tremendous threats to human health as well as seafood industry have been documented 
(12, 68). This opportunistic human pathogen, among the most severe of all foodborne 
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infections, causes primary septicemia and severe necrotizing wound infections with a 
mortality rate exceeding 50%, mostly in susceptible individuals having an underlying 
disease such as hemochromatosis, immune disorders, and diabetes. Infection is mainly 
caused by ingestion of raw or undercooked oysters but can also be the result of exposure 
of pre-existing wounds to seawater or seafood products (68, 187).  Death occurs in one 
or two days after the onset of disease unless an effective treatment can be implemented 
(68, 188).  
V. vulnificus biotype 1, primarily infecting humans, has been demonstrated to 
have degrees of virulence. Strains isolated from hospital patients, referred to as 
‘clinical,’ are highly virulent, whereas strains isolated from seawater, oysters, fish, and 
sediments, referred to as ‘environmental,’ are typically less virulent with some 
exceptions (23, 68, 189-193). Human tissue appears to select for more virulent clinical 
strains of V. vulnificus while those isolated from oysters exhibit a high level of virulence 
diversity (194). Virulence is conferred by several factors including the extracellular 
capsule polysaccharide (CPS), hemolysin/cytolysin, lipase, lecithinase, proteases, and 
collagenase as well as pili, and a flagellum (12, 37, 86, 97, 100, 178, 180). Capsular 
polysaccharide (CPS) is considered to play an important role in virulence of Vibrio 
vulnificus and its expression associated with the degree of virulence was shown in 
animal models because CPS enables microorganism to evade host immune response by 
avoiding phagocytosis and complement mediated immunity (87, 195). 
Hemolysin/cytolysin is responsible for lysis of host erythrocytes and the subsequent 
release of iron, in turn, stimulates transcription of the vvhA gene (196) and is required for 
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the efficient transcription of the extracellular protease VvpE. Extracellular enzymes play 
an important role in tissue necrosis (12). Pilli and flagella are used for attachment to host 
cells and formation of biofilms (12).  
Most studies of the virulence of V. vulnificus have relied upon isolate cultures. In 
the clinical environment V. vulnificus from tissues and blood are isolated on blood agars 
(69). For environmental samples, isolation methods involve an overnight enrichment in 
alkaline peptone water (APW), having a salinity of 10 PSU, that selects for halophilic 
bacteria (197). Enrichment is followed by streaking onto differential-selective agars. For 
several decades, thiosulfate-citrate-bile salts-sucrose (TCBS) agar was used to select for 
and isolate pathogenic vibrio species (70). Superior differential-selective media agars 
specific for V. vulnificus have since been developed and are now standard method. The 
first, cellobiose-polymyxin B-colistin (CPC) agar utilizes the resistance of V. vulnificus 
to colistin and polymyxin B for selection (198). Other standard agars are modifications 
of CPC. Tamplin et al. (75) modified CPC (mCPC) by reducing the amount of colistin to 
improve isolation success from environmental samples. Høi et al. (199) was able to 
significantly increase the isolation rates of V. vulnificus from seawater and sediments by 
removing polymyxin B from CPC to make CC agar.  
Because of the discovery of clinical and environmental strains it is important to 
know if standard methods for isolation (i.e. enrichment in liquid media followed by 
selective/differential agars) select for one strain over the other. Warner and Oliver (200) 
determined through genotyping of the virulence correlating gene (vcgC) that CPC and 
mCPC agars select preferentially for clinical strains. We were interested in knowing if 
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the prior overnight enrichment step with liquid media could preferentially select for 
clinical versus environmental strains of V. vulnificus. We compared APW, the traditional 
enrichment broth for V. vulnificus and other vibrios (201), to media employed for 
maintenance of V. vulnificus isolate cultures in the laboratory such as brain heart 
infusion broth (BHIB) (39, 181), and Luria Bertani broth (19, 78, 202).  
We hypothesized that different enrichment media will influence the selection for 
V. vulnificus clinical and environmental strains. Furthermore, we hypothesized that 
BHIB, which contains whole cells of calf brains and heart and has a higher iron 
concentration (24.5 µM) than other media we tested (~7 µM) , is most like human blood 
that selects for more virulent clinical strains. Normal iron concentrations of human 
serum are 14-32 μM in males and 10-28 μM in females and in persons with 
hemochromatosis 40 to 50 μM (203, 204). And, we wanted to know if the standard 
enrichment media APW is selective and would consequently influence the ratio of 
environmental versus clinical strains on differential-selective agars.  
Since standard isolation methods for V. vulnificus utilizes agars (i.e. CPC and 
mCPC) that select for clinical strains, we opted to use quantitative PCR (qPCR) assays 
to detect clinical strains directly in the enrichment media. QPCR allows for rapid 
detection of targeted sequences without the requirement of time-intensive isolation and 
has been used to examine V. vulnificus in the environment and in experimental settings 
(78, 185, 186). Moreover qPCR can quantify cells that might be excluded during 
isolation methods. We quantified the hemolysin/cytolysin gene, vvhA that is present in 
all V. vulnificus for total cell counts. Panicker et al. (84), who developed the assay, found 
 55 
 
 
it to have absolute specificity for V. vulnificus and high correlation (R
2
=0.98) with plate 
counts. The clinical variant of the virulence correlated gene (vcgC) was used to quantify 
clinical strains of V. vulnificus (184). The vcgC gene clinical variant has a 90% detection 
rate in clinical isolates (39). Two studies observed a high correlation (R
2
=0.98; R
2
=0.99, 
respectively) with the 16S rRNA type B gene (41) that is also present in clinical isolates.  
 
Materials and methods 
Isolate enrichments. This experiment was designed to test if clinical or 
environmental isolates were preferentially selected in enrichment media. Ten ml (3 
replicates) of APW broth having a salinity of 10 PSU (‘APW10’) and BHIB with an 
adjusted salinity of 10 PSU (‘BHIB10’) were inoculated with equal volumes (10 μl) of 
log phase (OD600 nm = 0.6) clinical (BUF7211) and environmental (98-640) strains of V. 
vulnificus (obtained from the U.S. FDA Gulf Coast Seafood Laboratory) and incubated 
for 20 hr at 35°C with shaking at 100 rpm. After incubation, a 2 ml aliquot was 
transferred into 2 ml tubes, centrifuged for 10 min at 10,000 rpm (4°C) to obtain a 
bacterial cell pellet and the supernatant was removed.  
 
Seawater enrichments. This experiment was designed to determine if 
enrichment media preferentially enriched clinical versus environmental V. vulnificus 
from environmental samples. Five ml (3 replicates) of APW having a salinity of 10 PSU, 
APW with 1/2 concentration of NaCl (‘APW5’; 5 PSU), BHIB (‘BHIB5’; 5 PSU), BHIB 
modified to a salinity of 10 PSU, and Luria Bertani broth (‘LB10’; 10 PSU), were 
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inoculated with five ml of seawater, collected from six locations in Galveston Bay (GB4 
lat 29.576801°/lon -94.934458°; GB6 lat 29.407004°; lon -94.806573°; GB12 lat 
29.478671°/lon -94.757890°; GB17 lat 29.231857°/lon -94.989873°; GB25 lat 
29.697525°/lon -94.783926°; GB29 lat 29.649323°/lon -94.811337°) in March, 
September, and November 2012 and vortexed then incubated for 20 hr at 35°C with 
shaking at 100 rpm. After incubation, a 2 ml aliquot was transferred into 2 ml tubes, 
centrifuged for 10 min at 10,000 rpm (4°C) to obtain a bacterial cell pellet and the 
supernatant was removed.  
 
DNA extraction. CTAB (3% cetyltrimethylammonium bromide, 500 μl) was 
added to the pellets. The tubes were incubated for an hour in a water bath at 60°C. 
During incubation time, the tubes were vortexed every 10 minutes to facilitate the lysis 
of bacterial cell walls. Next, 500 μl of chilled 24:1 choroform:isoamyl alcohol was 
added and vortexed on high for a good emulsion in order to dissolve the cell membrane 
of bacteria by binding lipids and proteins. The emulsions were centrifuged for 10 
minutes at 10,000 rpm (4°C). At the end of the centrifugation a top aqueous layer 
containing DNA, a middle interphase with cellular debris, and a lower organic phase 
were visible. Lipids and proteins are non-aqueous compound and DNA/RNA is aqueous 
compound so DNA was in the aqueous phase while cell debris and organic phase were in 
the middle and lower organic phases. The aqueous phase was carefully transferred into a 
new 2ml tube and 2/3 volume of ice-cold isopropanol was added. Tubes were gently 
tipped back and forward a few times to precipitate the DNA, and then stored at -20°C 
 57 
 
 
overnight. After overnight precipitation, the tubes were centrifuged 4°C 10,000 rpm for 
10 minutes, the supernatant (isopropyl) was decanted and the tubes were air dried for 2 
hr. Ice-cold ethanol (80%; 200 μl) was added to remove salts. The ethanol was decanted 
and the precipitated DNA was allowed to dry for 1-2 hours at room temperature with the 
tubes tipped downward and the caps off.  DNA was rehydrated overnight at room 
temperature with a buffer containing 10 mM Tris, 10 mM NaCl, and 0.5 mM EDTA. 
DNA extracts were stored at -20°C. 
 
Quantitative PCR. To determine total V. vulnificus, we quantified V. vulnificus 
specific hemolysin (VvhA) genes with a SYBR Green quantitative PCR (qPCR) assay 
(84). Total volume was 25 μL which contained 12.5 μL SYBR green Supermix 
(BioRad), 1 μM vvh-L primer (5’-TTCCAACTTCAAACCGAACTATGA-3’), 1 μM 
vvh-R primer (5’- ATTCCAGTCGATGCGAATA CGTTG-3’), 2.5 mM MgCl2 , 1 X 
BSA, and 2 μL of template DNA. The PCR reaction was performed in a SmartCycler 
(Cepheid) at 94°C for 2 minutes, followed by 45 cycles of at 94°C for 15 seconds, at 
56°C for 15 seconds and at 72°C for 25 seconds. Melt curve analysis was conducted 
from 60°C to 94°C at increments of 0.2°C per second. PCR positive control for qPCR 
runs and construction of standard curve was clinical strain BUF7211 obtained from the 
U.S. FDA Gulf Coast Seafood Laboratory.  
To determine clinical strains, we used a SYBR Green qPCR assay that quantifies 
the clinical variant of the virulence correlating gene (vcg) (205). Total volume was 20 
μL which contained 10 μL SYBR green Supermix (BioRad), 1 μM of each primer;  
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VCGF3 (5’-CGCCTTTGTCAGTGTTGCA-3’) and  
VCGB3 (5’-TAACGCGAGTAGTGAGCCG-3’), 2.5 mM MgCl2 , 1 X BSA, and 2 μL 
of DNA template. The PCR reaction was performed in a SmartCycler (Cepheid) at 95°C 
for 2 minutes for initial denaturation, followed by 45 cycles at 95°C for 20 seconds and 
60°C for 30 seconds and 72°C for 25 seconds. Melt curve analysis was conducted from 
60°C to 94°C at increments of 0.2°C per second. PCR positive control for qPCR and for 
construction of standard curve was clinical strain BUF7211 obtained from the U.S. FDA 
Gulf Coast Seafood Laboratory.  
Standard curves were created in the Smart Cycler according to manufacturer 
instructions with the same primer sets using genomic DNA extracted from graduated 
concentrations (10
1
, 10
2
, 10
3
, 10
4
, 10
5
, 10
6
, and 10
7
) of V. vulnificus strain BUF7211. 
Counts (CFU) of V. vulnificus were generated by the standard curve and any dilutions 
were figured into the back calculation to the original DNA extraction volume.  
Two sample T-test and One-way ANOVA (p<0.05) was conducted with STATA 
13.1 (StataCorp). For ANOVA Bartlett’s test was conducted a priori to ensure equal 
variances. Bonferroni post hoc test was used to determine differences in means (p<0.05).   
 
Results 
Isolate enrichments. VvhA concentration, as a proxy for V. vulnificus cells, was 
the same in enrichment media APW10 (1.5×10
6
±3.7×10
5
 CFU/ml) and BHIB10 
(1.6×10
6
±3.6×10
5
) (Fig. 4-1) (two-sample T-test; p=0.8695).  Percent vcgC genes was 
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higher in the BHIB10 medium (85.6±3.4%) than in the APW10 medium (47.3±7.6%) 
(Two-sample T-test; p=0.0234) (Fig. 6).  
 
 
Figure 6. Concentration of vvhA (CFU/ml) and % vcgC genes 
in enrichment media APW10 and BHIB10. Asterisk denotes 
significant difference p<0.05. 
 
Seawater enrichments. VvhA concentrations (CFU/ml) are presented in Fig. 7 
according to sampling date and station numbers. For samples collected on 3/22/12, no 
significant differences were observed between enrichments in samples GB12 and GB25 
(ANOVA; p=0.748, p=0.245, respectively). Concentrations in sample GB17 
enrichments APW5 and BHIB5 were significantly lower than APW10, BHIB10, and 
LB10 (ANOVA; p=0.0097). Total V. vulnificus (i.e. vvhA CFU/ml) in all samples ranged 
from 76±11 to 275±44 CFU/ml.  
* 
p=0.0234 
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For sample GB25, collected on 9/4/12, vvhA concentrations in enrichments 
APW10 (1,335±133 CFU/ml), BHIB10 (1,469±376 CFU/ml) and LB10 (1,026±145 
CFU/ml) were not significantly different from each other however they were 
approximately 4 to 6 fold higher (ANOVA; p=0.0026) than the other enrichments with 
APW5 and BHIB5. Enrichments APW10 (1,747±134 CFU/ml) and BHIB10 
(1,920±158) in sample GB29, collected on the same day, had significantly higher vvhA 
concentrations than all other enrichments (ANOVA; p=0.0001). And enrichment LB10 
(1,076±81) had significantly higher concentrations than APW5 (435±32 CFU/ml) and 
BHIB5 (422±92 CFU/ml) (Bonferroni post hoc test; p=0.020 and p=0.018, respectively) 
For samples collected on 11/4/12, GB4, GB6, and GB12, vvhA concentrations in 
the APW10 (183±23, 335±66, 478±45 CFU/ml, respectively), BHIB10 (150±10, 
368±57, 324±46 CFU/ml, respectively), and LB10 (132±14, 242±27, and 321±13 
CFU/ml, respectively) enrichments were not significantly different from each other but 
were approximately 3 to 4 fold higher (p=0.0002, p=0.0107, and p=0.0008, respectively) 
than the other enrichments, APW5 and BHIB5. 
The percentage of vcgC gene counts out of total V. vulnificus cell counts (i.e. 
vvhA) are presented in Fig. 8 according to sampling date and station numbers. All 
samples collected on 3/22/12 had low percentages (<20%) of the vcgC gene with no 
significant differences between enrichments.  
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Figure 7. VvhA CFU/ml in seawater enriched with APW10, APW5, BHIB10, BHIB5, and LB10 for samples 
collected 3/22/12, 9/4/12, and 11/4/12 analyzed with one-way ANOVA, p<0.05. Asterisk denotes significance of 
p<0.05 in Bonferroni post hoc test. 
 
 
Sample GB25 collected on 9/4/12 had significantly higher vcgC percentages in 
enrichment BHIB10 (68±6; p<0.01 Bonferroni post hoc test) than APW10 and LB10 
(49±6 and 33±9%, respectively), that were higher (p<0.05, Bonferroni post hoc test) 
than the other enrichments having ~10% (ANOVA; p=0.0006). Percent vcgC genes in 
the BHIB10 enrichment (70±3%; p<0.01 Bonferroni post hoc test) from sample GB29 
was significantly greater than all other enrichments APW10 (52±3%), APW5 (9±3%), 
BHIB5 (8±2%) and LB10 (46±2%) (ANOVA; p<0.0001).  
p=0.748 p=0.0097 
p=0.026 
p=0.245 
p=0.001 
* 
* 
* 
* * 
* * * 
p=0.0002 p=0.0107 p=0.0008 
* * * 
* * 
* * 
* * 
 62 
 
 
 
 
   
  
 
   
Figure 8. Percent vcgC in seawater enriched with APW10, APW5, BHIB10, BHIB5, and LB10 for 
samples collected 3/22/12, 9/4/12, and 11/4/12 analyzed with one-way ANOVA, p<0.05. Asterisk denotes 
significance of p<0.01 and double asterisk p<0.05 in Bonferroni post hoc test. 
 
 
Percent vcgC genes in enrichment BHIB5 from sample GB12 collected on 
11/4/12 was significantly lower (ANOVA p=0.03) than the other enrichments, which 
were equal to each other (p<0.05 Bonferroni post hoc test). While in samples GB4 and 
GB6, no differences in %vcgC was determined between enrichments APW10 and 
BHIB10 (p<0.01 Bonferroni post hoc test), but they were significantly greater than 
LB10 (p<0.05) that was higher than APW5 and BHIB5 (ANOVA; p=0.0002 and 
p=0.0007, respectively). 
p=0.8986 p=0.0745 
p=0.0006 
p=0.0002 p=0.0007 p=0.0299 
p<0.0001 
p=0.9441 
* 
** 
** 
* 
** 
** 
* 
* 
* 
** 
** ** 
* 
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Discussion 
As hypothesized, the BHIB10 medium selected for clinical strains of V. 
vulnificus likely due to the high iron content. This selection could be advantageous for 
studying virulence factors in V. vulnificus. The ratio of clinical to environmental strains 
in APW10 was roughly equal indicating that it is suitable for isolation and MPN 
enumeration. Selective-differential agars have also been found to enrich clinical over 
environmental strains. Warner and Oliver (200) determined through genotyping of the 
virulence correlating gene (vcgC) that CPC and mCPC agars preferentially select for 
clinical strains. Based upon the isolate enrichment results (Fig. 4-1), we can conclude 
that ratios of clinical to environmental strains in the seawater enrichments were 
reflective of the actual starting concentrations when using the APW10 medium.  
For seawater, the lack of significant differences between enrichments having 
different salinities observed in samples collected in March (Fig. 7) might be explained 
by seasonal strain predominance differences (i.e. clinical versus environmental). 
Previous studies of Galveston Bay (53) have found that ‘environmental’ strains (i.e. 16S 
rRNA type A) predominate (up to 100%) in seawater and oysters from the early spring 
(March) to early summer (June) as water temperatures rise from below 10°C up to 
~25°C and salinities are low (<10 PSU). Concentrations of V. vulnificus are also low in 
March (non-detectable to <10) and increase gradually with increasing water 
temperatures. Between late June and October, as temperatures increase to >25°C and 
salinities increase up to 30 PSU, there is a shift to a predominance (>70%) of ‘clinical’ 
strains (i.e. 16S rRNA type B, vgcC positive). Concentrations of V. vulnificus are also 
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highest in oysters (10
3
-10
4 
CFU/g) and seawater (~10
2
 CFU/ml) during this time. Then 
as temperatures begin to decrease again in early November (<20°C) but salinities are 
still >20 PSU, the ratio of clinical to environmental strains is roughly even. In 
November, concentrations of V. vulnificus also decline rapidly with decreasing 
temperatures. The low concentration of V. vulnificus and the low percentage of clinical 
strains (i.e. %vcgC) in the March enrichments agree with the findings of these studies 
and we detected <20% vcgC genes for all enrichment types (Fig. 8) indicating a 
predominance (>80%) of environmental strains. 
Salinity appeared to be the key factor that influenced the concentration of V. 
vulnificus in the enrichments from seawater samples collected in September and 
November. These samples when enriched with the higher salinity broths (APW10, 
BHIB10, and LB10) had higher vcgC gene percentages than the broths having 5 PSU. 
The question is whether salinity is selecting for clinical strains or if clinical strains were 
already predominant in the original sample. The answer may be both. Ambient salinities 
in the seawater used for these enrichments were 10 to 18 PSU higher than in the March 
samples (~10 PSU). Again, Lin and Schwarz (53), who examined 16S rRNA types 
(A/B) in Galveston Bay seawater and oysters, found a predominance of 16S rRNA type 
B strains in August to November with salinities ranging from 21 to 29 PSU and 
temperatures ranging from 23°C to 30°C. Similar observations were also made when 
examining clinical versus environmental strains in Galveston Bay oysters. The 5 PSU 
salinity in the enrichment broths APW5 and BHIB5 may have selected for 
environmental strains (i.e. 16S rRNA type A), or may have limited growth of clinical 
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strains as percent vcgC genes was lower in these treatments. Chase and Harwood (185) 
who examined the influence of temperature and salinity on clinical strains of V. 
vulnificus found that highest growth rate (3.97 generations/hr) was achieved at 
temperature of 37°C and salinity of 25 PSU. Growth rate at the same temperature but at 
a lower salinity of 5 PSU was significantly lower (2.03 generations/hr). At 10 PSU, 
growth rate (3.24 generations/hr) was still significantly higher than at 5 PSU.  
Enrichment with BHIB10 selected for a higher percentage of virulent clinical 
strains (i.e. vcgC positive) than the other enrichment media in the September samples. 
Percent clinical strains in the BHIB10 medium was ~20% higher than in the APW10 
medium and ~30% higher than in the LB10 medium. All of these media contain 1% 
oligopeptides derived from digests of protein, but BHIB also contains 50% infusions of 
calf brains and beef hearts that increase the iron content by 17.5 µM. The high iron 
content in BHIB stimulates cytolysin/hemolysin activity of V. vulnificus (196, 206) and 
induces production of flagellar proteins that are integral for adhesion and biofilm 
formation in V. vulnificus (207). This trend was weakly continued in the November 
samples with only one sample (GB6; Fig. 8) having significantly higher percent clinical 
strains in the BHIB10 medium. It is apparent that salinity also plays a role in selecting 
for clinical strains since the BHIB5 medium with lower salinity had 50-60% lower 
percent clinical strains than BHIB10. 
Different enrichment media selected for different ratios of clinical to 
environmental strains. However the enrichment of seawater results indicated that not 
only does the starting ratio matter, so does the salinity of the seawater inoculum. In other 
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words, seasonal differences in predominance of clinical or environmental strains in 
seawater influence the enrichment process. The selective preference of the BHIB10 
medium for clinical strains indicates that iron plays an important role in the infection of 
the human host. 
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CHAPTER V 
 
THE EFFECTS OF TEMPERATURE, PH AND IRON ON BIOFILM 
PRODUCTION BY VIBRIO VULNIFICUS 
Overview 
Due to the nature of Vibrio vulnificus infections, no studies of a biofilm-
associated form in this pathogen’s life cycle have been conducted. Biofilm formation by 
clinical and environmental reference strains of V. vulnificus were tested under different 
temperature (24°C, 30°C and 37°C), pH (5.5, 7.5, and 8.5) and iron concentration (18, 
30, 50, 100, and 200 μM) conditions. For all strains, biofilm production at 24°C was 
often two to three times greater than at 30°C and 37°C, in multiple trials. The lowest 
amount of biofilm production was observed at 37°C (p<0.001). Biofilm production by 
clinical strains was consistently higher (p<0.001) at 24°C than environmental strains. 
Highest growth rates of all strains occurred at 37°C. The general trend for the pH trials 
was for highest biofilm production at pH 5.5 by all strains when incubated at 24°C. 
When incubated at 37°C, highest biofilm production at pH 5.5 was observed in primarily 
clinical isolates (p<0.05) indicating a greater resistance to the acidic environment of the 
host gastrointestinal tract. Growth rates were lowest at pH 5.5 for environmental strains 
but for clinical strains there were no differences at pH 5.5, 7.5, and 8.5 demonstrating a 
tolerance to acidic and alkaline conditions. There was a strong, direct correlation 
between iron concentration in the growth medium and biofilm production by all strains 
tested (clinical R
2
=0.91, 0.94, and 0.98; environmental R
2
=0.83, 0.84, 0.96; p<0.001). 
 68 
 
 
However, no differences were observed between clinical and environmental strains. 
With regards to temperature and pH, higher biofilm production appears to be a trait of 
clinical strains and could be considered a virulence factor. The results of this study 
indicate that biofilm production by V. vulnificus may be important to survival in the 
marine environmental and the human host. 
 
Introduction 
 
 Vibrio vulnificus is a highly lethal, opportunistic human pathogen that is 
ubiquitous in marine coastal waters. Infection occurs from ingestion of raw or 
undercooked seafood or exposure of wounds to seawater containing this microorganism. 
Among healthy people V. vulnificus can cause severe gastrointestinal illness. In 
individuals with elevated serum iron or are immune-compromised, primary septicemia is 
the most lethal infection with a mortality rate of >50% (208, 209). Wound infections can 
progress rapidly to cellulites, bullae, and necrotizing fasciitis however the mortality rate 
is only about 25% (208). The mechanics of infection have not been well studied and it is 
not known if biofilm plays a role in the colonization of the human host or survival in the 
marine environment.  
Vibrio cholerae exhibits biofilm mode of growth not only in the aquatic 
environment but also in the intestinal tract of its human host (49, 51). Unlike V. 
cholerae, V. vulnificus do not prefer living in the small intestine but instead colonize 
wounds and blood serum, therefore biofilm formation in V. vulnificus has received little 
attention in the clinical setting due to the nature of the infections. And, there are no data 
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for biofilm formation by V. vulnificus in the marine environment. Instead, studies of 
biofilm formation by V. vulnificus have focused on the identification of proteins essential 
for biofilm development (i.e. pili, flagella, and outer membrane) rather than on 
environmental factors contributing to biofilm development (31, 46, 47, 134). 
Biofilm formation is considered a selective survival strategy of microbial 
communities for protection from nutrient deprivation, pH changes, oxygen radicals, 
disinfectants, and antibiotics (210), as well as for facilitating the complex dynamic 
interactions of close proximity between microorganisms, in particular the 
communication of the individual cells via signaling pathways (136). According to the 
CDC reports, approximately 65% of bacterial pathogens form biofilms and 80% 
according to National Institutes of Health (NIH). Biofilms are associated with a great 
number of serious chronic infections (141). Pathogens in biofilm exhibit more resistance 
to the clearance by human host defenses and antimicrobial treatments, since they are 
protected by the presence of the biofilm matrix that acts as a diffusion barrier (211, 212). 
Planktonic cells can be 1,000 times more susceptible to antibiotic treatments than 
biofilm associated cells (212, 213). The development of anti-biofilm therapeutics against 
biofilms is one of the most challenging tasks in medicine today (141).  
There is a considerable body of data demonstrating that the biofilm formation 
depends on various physical, chemical and biological parameters such as nutrient 
availability, pH, salinity, temperature, iron concentration, oxygen, quorum sensing and 
genetics (157, 160, 161, 214-217). Hostacka et al. (160) compared the effects of 
temperature (30°C and 37°C) and pH (from 5.5 to 8.5) on biofilm formation in different 
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bacterial species P. aeruginosa, Klebsiella pneumoniae, and Vibrio cholerae non-O1 and 
O1, and observed that an increase in pH significantly affected the production of biofilm 
in all the bacterial species and strains tested.  However temperature had no effect 
suggesting that genetic background plays a more important role in the development of 
biofilm than do environmental parameters. Di Bonaventura et al. (161) examined the 
effects of temperature, pH, and static-dynamic conditions on biofilm development of 51 
Stenotrophomonas maltophilia clinical isolates. They observed higher biofilm formation 
at 32°C than at either 18°C or at 37°C, and the amount of biofilm produced was 
significantly higher at pH 7.5 and pH 8.5 than at pH 5.5. This study also indicated that 
strain-to-strain differentiations, regardless of environmental factors, have a marked 
effect on the biofilm development of S. maltophilia. While most clinical strains of S. 
maltophilia produced biofilms, 2% of the clinical strains did not form biofilm under the 
same conditions. Seemingly, not all clinical strains have the potential to form biofilm, 
and environmental parameters and host factors are also important to enable the 
individual strains to form biofilm.  
Iron is one of the most important essential factors for the growth of 
microorganisms and involved in pathogenicity (208). Iron also plays an important role in 
biofilm development in several pathogens (157, 170, 171). Yang et al. (157) conducted a 
biofilm experiment to examine the effect of iron on biofilm development of P. 
aeruginosa and observed that 5 μM ferric chloride containing-media increased the 
biofilm mass of P. aeruginosa and the resistance to antimicrobials, while an increased 
concentration of iron up to 100 μM ferric chloride repressed the biofilm development 
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and exhibited decreased resistance to antimicrobial compounds. Musk et al. (170) also 
observed that an increase in iron concentration inhibited the expression of the genes 
required for biofilm formation of P. aeruginosa and addition of excess iron disrupted 
even the pre-existing biofilms. That study determined that a limited range of iron 
concentration from 1 μM to 100μM is required for the development of P. aeruginosa 
biofilm. Data from another study by Martinez (214) revealed that although 
supplementation of culture medium with 100μM iron dramatically increased the growth 
of individual S. maltophilia at 30°C and 35°C, elevated iron concentration in culture 
medium showed no decreasing or increasing effect on biofilm formation of S. 
maltophilia. On the other hand, Staphylococcus aureus, produces more biofilm with 
increasing iron concentration, up to 200 µM (165). 
In this study, we examined the effect of temperature, pH, and iron concentration 
on in vitro biofilm production by V. vulnificus. We compared biofilm production by 
clinical strains, isolated from infected patients, to environmental strains, isolated oysters. 
Clinical strains are generally more virulent than environmental strains (23). Biofilm 
production is not a virulence factor, however we hypothesized that clinical strains would 
produce greater amounts of biofilm than environmental strains as a superior means of 
survival in the human host and the marine environment. 
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Materials and methods 
Bacterial strains and growth conditions. Three clinical and three 
environmental reference strains (Table 4), obtained from Department of Health & 
Human Services (Dauphin Island, AL), were tested for biofilm production at different 
temperatures, pH and iron concentrations. Strains were maintained in Brain Heart 
Infusion Broth (BHIB; Bacto) at 37°C with shaking at 100 rpm with re-inoculation into 
fresh media every three days. In preparation for experimental trials, 100 μl from 
maintained cultures was inoculated into fresh BHIB (5 ml) and incubated for 12 hr at 
37°C with shaking at 100 rpm. To ensure that no contamination of strain cultures had 
occurred, strains were streaked onto BHIB agar plates and single colonies were verified 
with PCR and vibrio specific PCR primers (84).  
 
Table 4: V. vulnificus strains used in this study 
Strain ID Source 16S type 
99623 DP-F5 environmental AB 
99581 DP-C7 environmental A 
98640 DP-E9 environmental A 
ORL 8074 clinical B 
BUF 7211 clinical B 
FLA 8869 clinical B 
 
 
Experimental design. Brain heart infusion broth (BHIB) + seawater (16 PSU, 
pH 7) was autoclaved (15 min) in borosilicate tubes with lids and allowed to stand at 
room temperature overnight to ensure sterility. For the pH experiments, BHIB was 
adjusted to 16 PSU with NaCl because adjustment of BHIB + seawater to pH 8.5 
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resulted in a precipitate. pH of BHIB + NaCl was adjusted to 5.5, 7.5 and 8.5 by adding 
HCI or NaOH and measured with a Thermo Scientific Orion 350 PerpHecT® LogR® 
Meter. After pH adjustment, the media was reautoclaved for 15 mins. After autoclaving, 
pH of the media (20 μl) was retested with pH paper to ensure that pH adjustments were 
maintained. For the iron experiments, iron concentration of the BHIB + seawater 
medium was measured with an ICPMS (Xseries 2, Thermo Scientific) equipped with a 
Xt cone and PC
3
 spray chamber kit. Iron was quantified according to a calibration curve 
produced with ferric chloride standards. The iron concentration of BHIB + seawater was 
determined to be 18 μM which was supplemented with filter sterilized (0.2 μm polyether 
sulfone membrane filter) ferric chloride to achieve the experimental concentrations. 
To determine concentration of strains for experiments, 100 μl from log phase 
cultures was transferred to 96 well plates and the optical density (OD) was measured at 
600 nm with a Synergy 2 Multi-Mode Microplate Reader (BioTek). Adjustments were 
made to the concentrations to achieve an OD600nm of 0.6 (~1 × 10
7
 cells/ml) for the 
starting inoculum. Starting inoculum (20 μl) was pipetted into the glass tubes containing 
500 μl medium and the tubes were vortexed, then incubated for 48 hr under different 
temperature (24, 30, and 37°C), pH (5.5, 7.5, and 8.5), and iron concentration (18, 30, 
50, 100, and 200 μM) conditions. Normal iron concentrations of human serum are 14-32 
μM in males and 10-28 μM in females and in persons with hemochromatosis 40 to 50 
μM (203, 204), so we performed our experiment at concentrations relevant to human 
serum. Higher concentrations were tested to determine possible negative effects. Each 
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experiment was performed in two to three independent trials with 6 replicates per 
treatment. Non-inoculated media served as controls.   
 
Biofilm assay. The production of biofilm by different strains of V. vulnificus was 
determined using a modified crystal violet staining method (218). After the 48 hr 
incubation under the desired conditions, the culture medium in the borosilicate glass 
tubes was gently poured out not to disturb the biofilm ring. Each tube was gently washed 
four times with 2% NaCl to remove any non-adhered cells. Crystal violet (0.1%; 600 μl) 
was added to tubes and incubated 40 minutes at room temperature. Afterwards, the 
unbound crystal violet was carefully decanted and tubes were rinsed thoroughly 3-4 
times with 2% NaCl to remove the unbound dye (Fig 9). Biofilm-bound crystal violet 
was eluted with 600 μl of 98% ethanol for 10 minutes. Aliquots (100 μl) of the eluted 
dye were transferred to 96 well plates and absorbance was measured at 570 nm using a 
Synergy 2 Multi-Mode Microplate Reader (Biotek). When necessary, the eluted dye was 
diluted with ethanol for measurements and the final absorbance value was multiplied by 
the dilution factor after subtracting the OD reading from the control tubes.  
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Figure 9. Biofilm stained with 0.1% crystal violet. The image shows 
stained aggregate rings in borosilicate glass culture tubes before 
addition of 600 µl 98% EtOH. The greater thickness and darker color 
of the aggregate rings indicates higher biofilm formation produced by 
three environmental (numbers) and three clinical (letters) strains of V. 
vulnificus at 24°C, 30°C and 37°C, respectively. 
 
Growth rates. Growth rates at different temperatures and pH were measured. All 
conditions were the same as in biofilm experiments except the starting amount of 
medium was 1000 μl inoculated with 40 μl inoculum and incubated for 12 hours. 
Aliquots (100 μl) from tubes were transferred to 96 well plates every 4 hour and the OD 
was measured at 600 nm with a Synergy 2 Multi- Mode Microplate Reader (Biotek). 
Growth rate experiments were performed twice and the results were averaged. To 
convert OD to cell counts, V. vulnificus in aliquots were stained with DAPI (4',6-
diamidino-2-phenylindole), filtered onto 0.2  μm polycarbonate membranes, and then 
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counted with epifluorescence microscopy using a Zeiss Axioplan 2 microscope (Zeiss). 
Growth rates were calculated with the following formula: 
g = (log10 Nt - log10 N0) / log10
2 
 
Nt is the final cell count and N0 is the starting cell count.  
 
Statistical analysis. STATA (StataCorp) was used to evaluate statistical 
significance in the data. Bartlett’s test was conducted a priori to one-way ANOVA to 
ensure equal variances and the Bonferroni test was conducted post hoc to determine 
differences in means; p<0.05. Linear regression and the two-sample T-test were also 
used to evaluate the significance of the data; p<0.05 
 
Results 
Effect of temperature. Three trials were conducted to test the effect of 
temperature (24°C, 30°C, and 37°C) on biofilm production by three clinical and three 
environmental strains of V. vulnificus. pH of media was 7. The results of trial 1 are 
presented in Fig. 10 and Table 5, trial 2 in Fig. 11 and Table 6, and trial 3 in Fig. 12, 
Table 7. In all three trials, the amount of biofilm produced by all strains were found to be 
significantly different at all temperatures tested (one-way ANOVA, p<0.001). The 
amount of biofilm produced at 24°C by all strains was significantly higher (p<0.001) 
than those formed at both 30°C and 37°C. The lowest amount of biofilm production was 
observed at 37°C (p<0.001).  
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Comparison of combined clinical versus combined environmental strains (two-
sample T-test, p<0.05) found that mean differences of biofilm production by all clinical 
strains was significantly higher at 24°C than environmental strains in all three trials 
(p<0.001) (Tables 8-10). However at higher temperatures the results were not consistent. 
At 30°C, clinical strains in trials 2 and 3 produced significantly greater amounts of 
biofilm than environmental strains (p=0.008, p=0.032, respectively). At 37°C, clinical 
strains produced higher biofilm than environmental strains only in trial 2 (p=0.002). 
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Figure 10. Effect of temperature (°C) on biofilm production (means ±SD) by 
environmental (numbers) and clinical (letters) strains (1
st
 trial). 
 
 
 
Table 5. Effect of temperature on biofilm production by environmental (numbers) 
and clinical strains (letters); one-way ANOVA, means ± SD; p<0.05 (1
st
 trial). 
Strains 24°C 30°C 37°C p 
99623 8.9 ±1.0
1
* 5.6±0.7* 3.5±0.6* <0.001 
99581 11.3±0.9* 7.4±0.7* 4.9±1.4* <0.001 
98640 9.8±0.9* 6.0±0.6* 4.1±0.6* <0.001 
ORL 11.2±0.9* 5.6±0.5* 4.2±1.2* <0.001 
BUF 14.5±1.9* 7.2±0.7* 5.5±0.6* <0.001 
FLA 15.3±3.5* 7.9±1.1* 4.4±0.9* <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Figure 11. Effect of temperature (°C) on biofilm production (means ±SD) by 
environmental (numbers) and clinical (letters) strains (2
nd
 trial). 
 
 
 
 
Table 6. Effect of temperature on biofilm production by environmental (numbers) and 
clinical strains (letters); one-way ANOVA, means ± SD; p<0.05 (2
nd
 trial). 
Strains 24°C 30°C 37°C p 
99623 9.9±0.5
1
* 3.5±0.8* 1.9±0.7* <0.001 
99581 11.2±0.8* 6.3±0.2* 2.9±0.6* <0.001 
98640 14.4±1.3* 8.1±0.7* 5.1±0.2* <0.001 
ORL 18.8±0.9* 7.4±0.9* 5.9±0.5* <0.001 
BUF 15.6±0.8* 11.3±0.7* 4.8±0.8* <0.001 
FLA 17.2±1.8* 6.9±1.1* 4.3±0.7* <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Figure 12. Effect of temperature (°C) on biofilm production (means ±SD) by 
environmental (numbers) and clinical (letters) strain (3
rd
 trial). 
 
 
 
 
Table 7. Effect of temperature on biofilm production by environmental (numbers) 
and clinical strains (letters); one-way ANOVA, means ± SD; p<0.05 (3
rd
 trial). 
Strains 24°C 30°C 37°C p 
99623 7.8±0.6
1
* 3.7±0.2* 2.1±0.8* <0.001 
99581 13.1±0.4* 7.4±0.9* 2.6±0.5* <0.001 
98640 11.3±1.5* 6.4±0.6* 5.0±0.6* <0.001 
ORL 12.9±1.6* 4.7±0.5* 1.4±0.3* <0.001 
BUF 16.3±1.3* 8.2±0.7* 3.1±0.5* <0.001 
FLA 17.7±1.7* 8.7±0.4* 3.9±0.8* <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
 
 
 
 
0
5
10
15
20
25
99623 99581 98640 ORL BUF FLA
O
D
5
7
0
 n
m
 
Strain 
Temperature 
24 deg C
30 deg C
37 deg C
 81 
 
 
Table 8. Comparison of biofilm production by clinical vs 
environmental strains at different temperatures; two-sample T-test; 
means ± SD; p<0.05 (1
st
 trial). 
Temperature Clinical Environmental p 
24°C 13.6±2.9
1
* 10.0±1.3 <0.001 
30°C 6.9±1.2 6.4±0.9 0.166 
37°C 4.7±1.1 4.2±1.1 0.149 
1
Optical density at 570 nm 
*Significantly different 
 
 
 
Table 9. Comparison of biofilm production by clinical vs 
environmental strains at different temperatures; two-sample T-test; 
means ± SD; p<0.05 (2
nd
 trial). 
Temperature Clinical Environmental p 
24°C 17.2±1.8
1
* 11.8±2.1 <0.001 
30°C 8.5±2.2* 5.9±2.0 0.008 
37°C 4.9±0.9* 3.3±1.5 0.002 
1
Optical density at 570 nm 
*Significantly different 
 
 
 
 
Table 10. Comparison of biofilm production by clinical vs 
environmental strains at different temperatures; two-sample T-test; 
means ± SD; p<0.05 (3
rd
 trial). 
Temperature Clinical Environmental p 
24°C 15.7±2.5
1
* 10.8±2.5 <0.001 
30°C 7.2±1.9* 5.8±1.7 0.032 
37°C 2.8±1.2 3.3±1.4 0.346 
1
Optical density at 570 nm 
*Significantly different 
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Effect of pH. The effect of pH on biofilms produced by environmental and 
clinical strains of V. vulnificus was tested in medium with pH 5.5, 7.5 and 8.5, incubated 
at 24°C, for 48 hr (Figs. 13-15, Tables 11-13). In trial 1, environmental strains 99623 
and 99581 had significantly different biofilm production at all three pH (p<0.001) with 
highest production at pH 5.5.  For environmental strain 98640, highest biofilm 
production was at pH 5.5. Clinical strain ORL also had significantly different biofilm 
production at all three pH values (p<0.001) with highest biofilm production at pH 5.5. 
And highest biofilm production for clinical strains BUF and FLA was highest at pH 5.5 
and 8.5 (p<0.001). In trial 2, environmental strains 99623 and 99581 again had 
significantly different biofilm production at all three pH (p<0.001) with highest 
production at pH 5.5. However environmental strain 98640 had highest biofilm 
production at both pH 5.5 and 7.5. For clinical strain ORL, highest biofilm production 
was also at pH 7.5 and 5.5. Clinical strains BUF and FLA had highest biofilm 
production at pH 5.5 (p<0.001). In trial 3, all strains had highest biofilm production at 
pH 5.5.  The overall trend from all trials was for highest biofilm production at pH 5.5. 
Comparison of clinical to environmental isolates (two-sample T-test) revealed that 
significantly higher biofilm production occurred with clinical isolates at all pH values, 
except in one case (pH 5.5) from trial 2 (Tables 14-16).  
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Figure 13. Biofilm production by environmental (numbers) and clinical (letters) 
strains of V. vulnificus at different pH; means±SD (1
st
 trial). 
 
 
 
Table 11. Effect of pH on biofilm production by three environmental 
(numbers) and three clinical (letters) strains; means ± SD; one-way 
ANOVA; p<0.05 (1
st
 trial). 
Strains pH 5.5 pH 7.5 pH 8.5 p 
99623 15.4±1.8
1
* 4.7±0.8* 6.7±0.9* <0.001 
99581 18.9±1.6* 14.1±0.7* 11.9±1.1* <0.001 
98640 16.5±1.5* 10.9±1.4 11.3±0.9 <0.001 
ORL 23.3±0.9* 16.8±1.6* 14.7±1.1* <0.001 
BUF 19.2±1.4  15.9±0.8* 18.4±0.8 <0.001 
FLA 22.2±1.7 16.8±1.8* 19.8±1.5 <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Figure 14. Biofilm production by environmental (numbers) and clinical (letters) 
strains of V. vulnificus at different pH; means±SD (2
nd
 trial).  
 
 
 
Table 12. Effect of pH on biofilm production by three environmental 
(numbers) and three clinical (letters) strains; means ± SD; one-way ANOVA; 
p<0.05 (2
nd
 trial). 
Strains pH 5.5 pH 7.5 pH 8.5 p 
99623 13.2±0.8
1
*  11.5±0.9* 8.4±1.3* <0.001 
99581 21.0±1.9*  14.6±1.4* 11.2±1.2* <0.001 
98640 16.2±1.4  15.2±0.7 11.7±1.3* <0.001 
ORL 19.4±0.8  17.8±1.4 15.5±1.2* <0.001 
BUF 16.1±0.3* 13.9±1.7 13.2±0.6 <0.001 
FLA 20.2±2.2* 15.8±1.2* 13.4±0.6* <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Figure 15. Biofilm production by environmental (numbers) and clinical (letters) strains of 
V. vulnificus at different pH; means±SD  (3
rd
 trial).  
 
 
 
 
Table 13. Effect of pH on biofilm production by three environmental (numbers) 
and three clinical (letters); one-way ANOVA, means ± SD; p<0.05 (3
rd
 trial). 
Strains pH 5.5 pH 7.5 pH 8.5 p 
99623 4.4±1.0
1
*  2.3±0.6 2.9±0.5 <0.001 
99581 16.7±4.4* 9.5±2.4 6.5±0.8 <0.001 
98640 7.2±1.3* 5.7±0.7 5.1±1.3 <0.05 
ORL 13.2±1.3* 9.8±0.7* 6.8±0.6* <0.001 
BUF 6.6±1.2* 4.7±0.7* 3.3±0.6* <0.001 
FLA 22.7±3.2* 13.4±3.3 16.6±1.2 <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Table 14. Biofilm production by clinical vs environmental strains at 
different pH; two-sample T-test; means±SD, p<0.05 (1
st
 trial). 
pH Clinical Environmental p 
5.5 21.5±2.2
1
* 16.9±2.2 <0.001 
7.5 16.6±1.5* 9.9±4.1 <0.001 
8.5 17.7±2.5* 9.9±2.6 <0.001 
1
Optical density at 570 nm 
*Significantly different 
 
 
 
Table 15. Biofilm production by clinical vs environmental strains at 
different pH; two-sample T-test; means±SD, p<0.05 (2
nd
 trial). 
pH Clinical Environmental p 
5.5 18.6±2.2
1
 16.8±3.6 0.082 
7.5 15.9±2.1* 13.7±1.9 <0.005 
8.5 14.0±1.3* 10.4±1.9 <0.001 
1
Optical density at 570 nm 
*Significantly different 
 
 
 
 
 
Table 16. Biofilm production by clinical vs environmental strains at 
different pH; two-sample T-test; means±SD, p<0.05 (3
rd
 trial). 
pH Clinical Environmental p 
5.5 14.1±7.1
1
* 9.4±5.9 <0.05 
7.5 9.3±4.1* 5.9±3.3 <0.01 
8.5 8.9±5.9* 4.9±1.7 <0.01 
1
Optical density at 570 nm 
*Significantly different 
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Effect of pH at 37°C. We tested biofilm production by clinical and 
environmental strains of V. vulnificus at different pH but incubated at 37°C, the average 
human body temperature. In trial 1 (Fig. 16, Table 17) no significant differences were 
observed between pH values for all environmental strains. Within clinical strains, isolate 
BUF produced a significantly greater amount of biofilm at pH 5.5 (6.0±0.3; p<0.001) 
while there were no differences for the other clinical strains ORL, and FLA. In trial 2 
(Fig. 9, Table 15) within environmental strains, isolate 99581 produced significantly 
greater biofilm at pH 5.5 than the other isolates. Isolate 98640 produced more biofilm at 
pH 5.5 and 7.5 (4.3±0.7 and 3.8±0.3, respectively; p=0.0002). Within clinical strains, 
isolates BUF and FLA produced more biofilm at pH 5.5 (11.7±0.7 and 4.5±0.4; 
p<0.0010) than at pH 7.5 and 8.5. A two-sample T-test comparison of clinical to 
environmental isolates (Tables 19 and 20) found that clinical isolates produced 
significantly more biofilm at pH 5.5 and 8.5 (p=0.016) in trial 1. And, in trial 2, clinical 
strains produced more biofilm at pH 5.5 (6.3±3.9; p=0.0488) than environmental 
isolates.  
 
 
 
 
 
 
 
 88 
 
 
 
Figure 16. Biofilm production by environmental (numbers) and clinical (letters) 
strains of V. vulnificus at different pH incubated at 37°C; means±SD  (1
st
 trial). 
 
 
 
Table 17. Effect of pH incubated at 37°C on biofilm production by three environmental 
(numbers) and three clinical (letters); one-way ANOVA, means ± SD; p<0.05 (1
st
 trial). 
Strains pH 5.5 pH 7.5 pH 8.5 p 
99623 2.3±0.4
1
 2.1±0.6 2.0±0.5 0.4825 
99581 2.5±0.7 3.6±0.8 3.1±0.7 0.1028 
98640 3.1±0.5 3.2±0.5 2.5±0.4 0.0609 
ORL 2.5±0.5 2.8±0.5 3.5±0.6 0.0516 
BUF 6.0±0.3* 4.9±0.5 3.9±0.4 <0.001 
FLA 2.8±0.8 2.1±0.4 3.0±0.7 0.0666 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Figure 17. Biofilm production by environmental (numbers) and clinical (letters) strains 
of V. vulnificus at different pH incubated at 37°C; means±SD (2
nd
 trial). 
 
 
 
Table 18. Effect of pH incubated at 37°C on biofilm production by three environmental 
(numbers) and three clinical (letters); one-way ANOVA, means ± SD; p<0.05 (2
nd
 trial). 
Strains pH 5.5 pH 7.5 pH 8.5 p 
99623 2.6±0.5
1
 2.3±0.4 2.2±0.2 0.1454 
99581 6.1±0.3* 5.1±0.6 4.6±0.5 0.0003 
98640 4.3±0.7 3.8±0.3 2.8±0.3* 0.0002 
ORL 2.9±0.3 3.4±0.2 3.9±0.5* 0.0018 
BUF 11.7±0.7* 5.6±0.4* 3.4±0.8* <0.001 
FLA 4.5±0.4* 2.5±0.6 2.6±0.3 <0.001 
1
Optical density at 570 nm 
*Significantly different as determined by Bonferroni post hoc test. 
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Table 19. Biofilm production by clinical vs environmental strains at 
different pH incubated at 37°C; two-sample T-test; means±SD, p<0.05 
(1
st
 trial). 
pH Clinical Environmental p 
5.5 3.8±1.7
1
* 2.6±0.7 0.016 
7.5 3.3±1.3 2.9±0.9 0.363 
8.5 3.5±0.6* 2.7±0.6 0.0002 
1
Optical density at 570 nm 
*Significantly different 
 
 
 
Table 20. Biofilm production by clinical vs environmental strains at 
different pH incubated at 37°C; two-sample T-test; means±SD, p<0.05 
(2
nd
 trial). 
pH Clinical Environmental p 
5.5 6.3±3.9
1
* 4.3±1.5 0.0488 
7.5 3.8±1.3 3.7±1.2 0.7941 
8.5 3.3±0.8 3.1±1.1 0.6727 
1
Optical density at 570 nm 
*Significantly different 
 
 
Effect of iron. The effect of iron on biofilm production by V. vulnificus was 
tested by the addition of ferric chloride (FeCl3) at 18, 30, 50, 100, and 200 µM. Linear 
regression analysis revealed that biofilm formation increased with increasing ferric 
chloride concentration (Figs. 18 and 19). The means of biofilm production with standard 
deviations are summarized in Tables 21 and 22. In trial 1, R
2
 values of clinical strains 
ORL, BUF, FLA were high (0.98, 0.91, 0.94, respectively, p<0.001) indicating a strong 
correlation between biofilm production and iron concentration. R
2
 value for 
environmental strain 98640 was also high (0.96) but was lower for environmental strains 
99623 and 99581 (0.83 and 0.89, respectively). R
2
 values in trial 2 were moderate for all 
strains ranging from 0.75 to 0.86. The overall trend from both trials indicated that 
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biofilm production increases with increasing iron concentration with no repression at 
higher concentrations (>50 µM). Comparison of clinical to environmental strains (two-
sample T-test) found no differences in biofilm production as a response to increasing 
iron concentration (data not shown). 
 
   
   
Figure 18. Biofilm production by environmental (numbers) and clinical (letters) strains of V. vulnificus 
with increasing ferric chloride concentrations according to regression analysis (1
st
 trial).  
 
 
 
Table 21. Effect of ferric chloride on biofilm production by environmental (numbers) 
and clinical (letters) strains; linear regression, means ± SD, p<0.05  (1
st
 trial). 
strains 18µM 30µM 50µM 100µM 200µM p R
2
 
99623 8.3±0.7
1
 8.3±0.9 8.9±0.6 11.6±1.2 13.5±1.3 <0.001 0.83 
99581 7.2±0.9 10.7±0.9 11.6±1.2 13.3±0.7 18.7±0.9 <0.001 0.89 
98640 6.9±0.7 8.9±0.6 10.4±0.7 12.0±0.9 19.5±0.5 <0.001 0.96 
ORL 7.9±0.6 8.6±0.6 9.4±0.7 12.4±0.3 18.5±0.8 <0.001 0.98 
BUF 7.9±0.3 8.9±0.3 9.4±0.2 11.4±0.9 16.7±2.3 <0.001 0.91 
FLA 9.4±0.6 10.3±1.0 11.1±1.1 14.1±0.8 17.6±0.6 <0.001 0.94 
1
Optical density at 570 nm 
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Figure 19. Biofilm production by environmental (numbers) and clinical (letters) strains of V. vulnificus 
with increasing ferric chloride concentrations (2
nd
 trial). 
 
 
 
 
 
Table 22. Effect of ferric chloride on biofilm production by environmental (numbers) 
and clinical (letters) strains; linear regression, means ± SD, p<0.05  (2
nd
 trial). 
Strains 18µM 30µM 50µM 100µM 200µM p R
2
 
99623 7.2±0.8
1
 8.4±1.7 10.4±1.6 11.1±0.7 13.6±0.9 <0.001 0.75 
99581 6.6±0.9 9.9±1. 10.1±1.2 11.8±0.7 15.7±1.2 <0.001 0.83 
98640 7.8±0.9 9.5±0.7 11.2±0.5 11.9±1.0 14.9±1.6 <0.001 0.81 
ORL 7.5±0.7 8.9±0.5 9.9±1.1 11.5±0.3 13.6±1.3 <0.001 0.83 
BUF 7.3±1.0 9.3±1.2 9.9±0.1 10.7±0.8 13.5±1.4 <0.001 0.77 
FLA 8.5±0.7 10.2±0.4 10.7±1.8 12.9±0.4 16.1±1.5 <0.001 0.86 
1
Optical density at 570 nm 
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Growth rate. Growth rates of environmental and clinical strains were 
determined during biofilm production at different temperatures and pH. Although the 
highest biofilm production occurred at 24°C, the highest growth rate was observed at 30 
and 37°C for most strains (Table 23). For all environmental strains, lowest growth rate 
was observed at pH 5.5 with highest growth rates at pH 7.5 (Table 24). No significant 
differences were observed in the growth rates of the clinical strains at different pH 
values.  
 
Table 23. Growth rates (generations/hr) of environmental (numbers) and clinical (letters) 
strains grown at different temperatures; one-way ANOVA, means ± SD, p<0.05. 
Strain 24°C 30°C 37°C p 
99623 0.329±0.001* 0.390±0.005 0.425±0.012 0.0028 
99581 0.339±0.016* 0.403±0.003 0.426±0.000 0.0059 
98640 0.339±0.016 0.375±0.007 0.425±0.003* 0.0083 
ORL 0.346±0.012* 0.397±0.006 0.423±0.003 0.0059 
BUF 0.350±0.003* 0.415±0.005 0.432±0.008 0.0232 
FLA 0.361±0.002* 0.412±0.001* 0.425±0.002* 0.0002 
*Significantly different as determined by Bonferroni post hoc test. 
 
 
 
Table 24. Growth rates (generations/hr) of environmental (numbers) and clinical (letters) 
strains grown at different pH; one-way ANOVA, means ± SD, p<0.05. 
Strain 5.5 7.5 8.5 p 
99623 0.306±0.001* 0.407±0.005* 0.358±0.016* 0.0048 
99581 0.330±0.01* 0.436±0.002 0.400±0.015 0.0052 
98640 0.350±0.017* 0.421±0.006 0.398±0.003 0.0170 
ORL 0.358±0.026 0.431±0.014 0.392±0.004 0.0527 
BUF 0.368±0.03 0.442±0.001 0.418±0.01 0.0587 
FLA 0.375±0.04 0.437±0.036 0.408±0.018 0.3120 
*Significantly different as determined by Bonferroni post hoc test. 
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Discussion 
 
For all strains, biofilm production at 24°C was often two to three times greater 
than at 30 and 37°C in all three trials. Higher amount of biofilm production at lower 
temperature may be explained by high-frequency spontaneous phase variation of V. 
vulnificus. Grau et al. (218) defined a new phenotypic variant of this bacterium called 
the rugose variant or phenotype which is formed from opaque and translucent strains 
when they are continually cultivated at lower temperatures. This variant makes copious 
amounts of biofilms at the air-broth-glass interface as well as an aggregate ring. The 
highest biofilm production at 24°C in our study is consistent with these findings. 
However highest growth rate for most strains occurred at 30°C and 37°C, thus we 
assume that biofilm production is more related to switching events between different 
phenotypes of V. vulnificus rather than growth kinetics. Also, it is more likely that more 
cellular energy is devoted to biofilm production at 24°C than to cell replication. Upon 
comparing clinical and environmental strains, we observed that clinical strains produced 
significantly more biofilm than environmental strains at 24°C (p<0.001). However at 
30°C and 37°C biofilm production was not different, at least half the time. We propose 
that clinical strains of V. vulnificus form biofilms for protection in natural marine 
environments, when temperatures fall below 25°C. No data is available for V. vulnificus 
in this regard, but one study highlighted the importance of biofilm forming potential of 
Vibrios for their colonization and extended survival in the ex vivo marine environment 
(51). In experiments similar to ours, Townsley and Yildiz (159) tested biofilm formation 
by V. cholerae and found that biofilms produced at low temperatures (15°C and 25°C), 
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like those experienced in the aquatic habitat, had increased biomass and thickness and 
were more structured compared with those formed at 37°C. Another study (160) 
determined that V. cholerae produced slightly higher biofilm even at 30°C compared to 
37°C. It is also the rugose variant of V. cholerae that produces well-developed biofilms 
and has increased levels of resistance to several aquatic environmental stresses (219). 
Although biofilm production by all strains was lower at 37°C, this result should not be 
overlooked since it demonstrates the possibility of a biofilm form for V. vulnificus in the 
human host that would be important for survival in the gastrointestinal tract. In V. 
cholerae, biofilm architecture is essential for survival in the stomach and then for 
attachment in the small intestine (50). And, in biofilm form, V. cholerae virulence is 
several orders of magnitude higher than in planktonic forms (49, 50).  
V. vulnificus, like many gram negative bacteria, possesses several enzymes that 
neutralize low pH environments by breaking down amino acids to amines and CO2  as 
well as scavenge for superoxide radicals (208). We found that all V. vulnificus strains 
produced about 33% more biofilm at pH 5.5 than at pH 7.5 or 8.5 (incubated at 24°C), 
which may be an additional protective response at lower pH. V. cholerae produces 
biofilm for protection in the presence of bile acids (162) that normally restrict bacterial 
growth in the small intestine (163). pH effects attachment of V. cholerae to surfaces. 
Attachment and adhesion to inert or living surfaces are the first steps for biofilm 
formation. Attachment rate of V. cholerae to zooplankton was examined under various 
pH conditions and the optimum attachment was observed at lower pH scale (pH 2) while 
increasing pH decreased the attachment rate (34). We did not examine attachment rate in 
 96 
 
 
V. vulnificus but the production of biofilm in the gastrointestinal tract could facilitate 
attachment to the intestinal epithelium. Our work with V. vulnificus also found that more 
virulent clinical strains produced significantly more (25-50%) biofilm at all pH values 
tested when compared to less virulent environmental strains. In a similar study, a subset 
of more virulent strains, including a hyper-virulent ST-17 clone, of Streptococcus 
agalactiae were found to produce more biofilm under acidic pH than the rest of the 
strains tested (220). And, in our study, unlike environmental strains that had lower 
growth rates at pH 5.5, growth rates of clinical strains were not different at pH 5.5, 7.5 
or 8.5 indicating a resistance to acidic and alkaline environments.  
At 37°C, the average temperature of the human body, both clinical and 
environmental strains produced biofilm at all pH values (Tables 14 and 15). These 
findings are promising because the acidic gastrointestinal tract may drive clinical strains 
of V. vulnificus to form biofilm-like aggregates, as in the case in V. cholerae infections. 
One environmental isolate and two clinical isolates produced significantly higher biofilm 
at pH 5.5 with one clinical isolate (BUF) producing roughly two times more biofilm than 
all other strains. And, clinical strains, combined, produced more biofilm at pH 5.5 than 
environmental isolates indicating their greater resistance to a low pH environment such 
as the stomach and small intestine. These differences could be translated as increased 
virulence in these strains. There is evidence for higher virulence associated with 
increased biofilm production in V. cholerae. Wild type strains O395 and El Tor 6706, 
classical O1 and El Tor O1 biotypes, respectively, responsible for the last seven cholera 
pandemics, produce significantly more biofilm than less virulent variant strains (221).  
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Iron regulates biofilm formation by several human pathogens (157, 165-167). 
Our study found a direct correlation between free iron concentration in growth medium 
and biofilm production by V. vulnificus, although there were differences in the R
2 
values 
between trials. We did not observe any negative effects of elevated iron concentrations 
(i.e. 50, 100 and 200 µM) on biofilm production, instead higher amounts of biofilm were 
produced confirming the ferrophilic nature of V. vulnificus (116) and provides a possible 
in vivo reaction to high serum iron concentrations. To our knowledge there are no data 
regarding biofilm formation by V. vulnificus in human serum. However, biofilms may 
play a role in attachment to the intestinal epithelium and subsequent necrosis. Biofilm 
may also be necessary for colonization of open or bleeding wounds. It is known that 
bacterial biofilms colonize wounds (222) and prevent the healing process by producing 
proteases thereby prolonging the inflammatory response (223). Bacterial cells in biofilm 
are also significantly more resistant to antibiotics and host immune defenses than 
planktonic cells and persist in wounds (134, 222, 224). S. aureus, that forms biofilms in 
chronic wounds (168) and is one of the most frequently isolated pathogens associated 
with nosocomial sepsis (169), also produces more biofilm with increasing iron 
concentration, up to 200 µM (165). However, other pathogens like P. aeruginosa have 
limits and produce begin to produce less biofilm at higher concentrations >100 µM 
(157).  
Non-transferrin bound iron is necessary for V. vulnificus growth in human serum. 
Kim et al. (116) determined that non-transferrin bound iron is required for initiation of 
V. vulnificus growth. V. vulnificus is killed by serum from healthy individuals but grows 
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rapidly in serum from patients with high concentrations of free iron (225, 226). In 
patients with hemochromatosis, the serum contains a pool of freely available iron (227). 
During infection, iron availability increases as intracellular iron is released by cell 
destruction by V. vulnificus-specific hemolysin/cytolysin. Iron stimulates transcription of 
the vvhA gene that encodes for more hemolysin/cytolysin and is required for the efficient 
transcription of extracellular proteases that are also involved in cell destruction (196, 
207).  
Free iron is also important for the formation of biofilm by V. cholerae and is 
required for switching from smooth cells to the rugose variant that produces the EPS 
matrix of biofilm (167). The loss of the flagellum in the switching from smooth to 
rugose variant triggers the production of EPS by V. cholerae (228). And in non-motile, 
rugose V. cholerae, production of toxin-coregulated pili, cholera toxin, and cell-
associated hemolysin are increased (229). Iron also controls the adhesion of V. vulnificus 
to biotic and abiotic surfaces. There is a direct correlation between iron content in 
growth medium and production of flagellar proteins that are integral for adhesion and 
biofilm formation in V. vulnificus (207). A comprehensive study is needed to explain the 
role of iron in development of biofilm by V. vulnificus with consideration of high-
frequency phenotypic switching events from smooth or opaque phenotypes to the rugose 
variant.  
Due to the nature of V. vulnificus infections, no studies of a biofilm form in this 
pathogen’s life cycle have been conducted. The results of our study bring to light the 
possibility of biofilm formation by V. vulnificus in the marine environment as well as in 
 99 
 
 
vivo. Although all strains produced biofilms at 37°C, host body temperature, higher 
biofilm was produced at 24°C, a temperature that would be encountered in the marine 
environment. We did not test substrate but did observe that no biofilm is formed by V. 
vulnificus on plastic surfaces. Substrate type may be key to observing biofilm formation 
by V. vulnificus in the marine environment. There was a trend for acidic pH, typical of 
the gastrointestinal tract, to stimulate highest biofilm production by both clinical and 
environmental strains but clinical strains produced more biofilm both at 24°C and 37°C. 
Free iron, typical of hemochromatosis, also plays a strong role in biofilm production in 
V. vulnificus, which may facilitate infection of open wounds and perhaps in blood. 
Higher biofilm production appears to be a trait of clinical strains and could be 
considered a virulence factor. The results of this study indicate that biofilm production 
by V. vulnificus may be important to survival in the marine environmental and the 
human host. 
 
 
 
 
 
 
 
 
 
 100 
 
 
CHAPTER VI 
 
DIFFERENTIAL EXPRESSION OF VVHA AND CPS OPERON ALLELE 1 
GENES IN VIBRIO VULNIFICUS UNDER BIOFILM AND PLANKTONIC 
CONDITIONS 
Overview 
Examination of genes encoding for the virulence factors, hemolysin/cytolysin 
(vvhA) and capsular polysaccharide (CPS allele 1), during biofilm formation revealed 
that their expression was influenced by maturity of the biofilm as well as by temperature.  
At 24°C, expression of vvhA during biofilm formation was low between 4 and 12 h but 
increased 10 fold by 24 h to (5.1×10
4
±6.3×10
3
 mRNA copies/ml) as the biofilm 
matured. Compared to planktonic cells, expression of vvhA during biofilm formation at 
24°C was initially up-regulated at 4 h (1.07±0.00-fold) but then was down-regulated 
almost four-fold during the intermediate and mature stages of biofilm formation. In 
contrast, vvhA expression at 37°C was up-regulated almost four-fold in the early stages 
(4 and 6 h) of biofilm formation and remained two-fold up-regulated by 24 h even as the 
biofilm was deteriorating. CPS allele 1 expression at 24°C during biofilm formation was 
up-regulated (+1.50±0.18-fold) during the initial attachment phase of the cells but was 
strongly down-regulated during the intermediate phases at 8 and 10 h (74.42±42.16-fold 
and -453.76±193.32-fold, respectively) indicating that capsular polysaccharide (CPS) is 
not important to intermediate biofilm architecture. Interestingly, as the biofilm matured 
by 24 h, expression of CPS allele 1 was again up-regulated (+1.88±1.07) indicating that 
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CPS plays a role in mature biofilm. At 37°C, CPS allele 1 expression was significantly 
up-regulated (up to 10
5
) during biofilm formation indicating that the biofilm form of V. 
vulnificus may be preferred over the planktonic form in the human host. 
 
Introduction 
Vibrio vulnificus a naturally occurring marine pathogen accounts for 95% of all 
seafood related deaths in the United States, and causes the highest-death rate of any 
food-borne disease (8, 21). Forms of illness after ingestion of V. vulnificus are typically 
gastrointestinal (gastroenteritis) presented as vomiting, diarrhea, and severe abdominal 
pain, but if not treated, can rapidly infect the bloodstream (septicemia) within 24 to 48 hr 
resulting in fever, chills, blistering skin lesions (bullae), tissue necrosis, and death (2, 13, 
67). Infections can also be caused by exposure of pre-existing or fresh wounds to 
seawater containing V. vulnificus or by handling seafood (2). The mortality rate for 
primary septicemia, the most lethal form of infection, is greater than 50% after 
consumption of raw or undercooked oysters having high enough titers of V. vulnificus 
cells, and it can result in higher mortality rate in people who are immuno-compromised 
or have an underlying disease such as cancer, diabetes, hepatic disorders, 
hemochromatosis, thalassemia, and alcoholism (12). After first indications of infection, 
death from septicemia typically occurs within one or two days (37, 68). Exposure of pre-
existing or fresh wounds to seawater containing V. vulnificus can also lead to infection 
and a 25% mortality rate in people with wound infections has been observed (13). 
Wound infection is thought to occur as a consequence of seafood handling, fishing, 
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boating, swimming, or wading (2, 67).  Virulence in V. vulnificus varies between strains. 
Strains isolated from hospital patients, referred to as ‘clinical’, are highly virulent 
whereas strains isolated from seawater, oysters, fish and sediments, referred to as 
‘environmental’ are typically less virulent with some exceptions (23, 68, 189-193).  
Due to the nature of infections (i.e. septicemia and wound infections) the biofilm 
form in the life cycle of V. vulnificus has largely been ignored. A few studies of biofilm 
formation by V. vulnificus have focused on the identification of proteins essential for 
biofilm development (pili, flagella, and outer membrane) (31, 46, 47, 134). One study, 
(230) examined the influence of nutrient levels, NaCl concentration, and temperature 
on biofilm formation and found that different broths and addition of glucose 
affected attachment of V. vulnificus as did incubation at different temperatures but 
not different salinities. In our previous study we demonstrated that V. vulnificus 
produces robust biofilms at 24°C indicating a potential role for biofilms in protection of 
this pathogen in the marine environment, and also produce biofilm at 37°C and at acidic 
pH, typical of the human host gastrointestinal tract.  
As a follow up study to our previous work, we examined the expression of two 
important virulence factors, hemolysin/cytolysin (vvh) and capsular polysaccharide 
(group 1), during biofilm formation in V. vulnificus. We wanted to know if virulence of 
V. vulnificus, as represented by expression of genes encoding for these virulence factors, 
is affected by biofilm formation. Biofilm formation costs bacteria energy that could be 
used for cellular growth (135, 231, 232) and perhaps production of virulence factors. 
The up or down regulation of virulence genes during biofilm formation differ between 
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bacterial species. In some toxic Escherichia coli strains, several virulence-associated 
genes are up-regulated in biofilms versus planktonic forms including a pathogenicity 
island proposed to be associated with biofilm formation (233). However in 
Staphylococcus aureus, genes encoding for toxins and proteases are down-regulated in 
biofilm conditions (234). 
Vvh facilitates iron acquisition by lyses of hemoglobin (109, 115). Purified vvh 
has also been found to increase vascular permeability, skin damage, and death rate in 
mice (35, 43). Moreover, the inoculation of vvh into mouse epithelial cells resulted in 
skin damage similar to those resulting from infection of V. vulnificus (35). Vvh also 
stimulates production of guanylate cyclase in the host, causing an increase in the amount 
of intracellular cyclic GMP, and consequently vasodilation (127, 128). Additionally, vvh 
functions as a “pore forming protein” in cellular membranes (129).  
Capsular polysaccharide (CPS) is a key virulence factor for human and animal 
pathogens. CPS is considered as the most significant virulence determinant of V. 
vulnificus because it allows this pathogen to evade non-specific host immune response 
by avoiding complement mediated phagocytosis (37, 68, 235) and specific host 
immunity in which there is poor antibody response to the capsule (235). CPS, together 
with lipopolysaccharide, is thought to play an important role in septic shock formation 
by stimulating the expression of inflammation-associated cytokines (89). The presence 
of a capsule appears to be associated with more invasive V. vulnificus, since 
encapsulated forms are more commonly found among clinical isolates than among 
environmental isolates (28). CPS also plays a role in biofilm formation. CPS is important 
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for the initial coverage of surfaces by bacteria during adhesion and the construction of 
mature biofilm architecture (140, 236, 237) and in regulating size of the biofilm (238). 
We examined the expression of vvhA and CPS Operon allele 1 genes in a clinical 
strain of V. vulnificus during biofilm formation and in planktonic cells. VvhA encodes for 
V. vulnificus-specific hemolysin/cytolysin. There are two alleles that encode for Group I 
capsules in V. vulnificus and are strain-specific (86). Allele 1 is found in strains 
undergoing rapid phase switches between opaque (virulent) and translucent (avirulent) 
colonies. Allele 2 is found in strains that switch at lower rate and frequency. Allele 
specificity is also indicative of strain origin. Allele 1 is found in 87% of clinical strains 
(highly virulent) whereas allele 2 is found in 87% of environmental strains (less 
virulent).  
 
Materials and methods 
Brain Heart Infusion Broth (BHIB) mixed 1:1 with seawater (0.5 ml; 16 PSU; pH 
7.5) in borosilicate glass test tubes was inoculated (approximately 10
3 
cells) with a 
clinical strain of Vibrio vulnificus (FLA 8869) obtained from the U.S. FDA Gulf Coast 
Seafood Laboratory. Borosilicate tubes were used for biofilm formation and 
polyethylene tubes for planktonic growth of strain FLA. We found in previous 
experiments that polyethylene inhibits biofilm formation by V. vulnificus. Experimental 
design included 3 replicates for mRNA quantification of vvhA and CPS allele 1 (86) 
genes during biofilm formation, 3 replicates for biofilm measurement, and 3 replicates 
for mRNA quantification of vvhA and CPS allele 1 genes in planktonic FLA. Additional 
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replicates were used for bacterial cell density determination. Inoculated media was 
incubated at 24°C and 37°C on a shaker (120 rpm). Aliquots were sampled at 0, 4, 6, 8, 
10, 12, and 24 hr.  
 
RNA extraction. Total RNA was extracted from bacterial cells by first 
incubating with lysozyme (10 mg/ml) at 48°C for 40 mins, then followed by addition of 
3% CTAB (cetyltrimethylammonium bromide) and incubated another 40 mins at 60°C 
with gentle mixing. The aqueous phase containing the nucleic acids was separated with 
chloroform:isoamyl and alcohol (24:1) and transferred to a new tube. Nucleic acids were 
precipitated with isopropanol (100%), collected by centrifugation and then treated with 
80% ethanol to remove salts. After drying (3 mins) the nucleic acids were rehydrated in 
RNase/DNase free water (Sigma) and concentrations determined spectrophotometrically 
(NanoDrop ND-1000). To the greatest extent possible, precautions were taken to prevent 
RNase degradation of RNA. DNA removal with DNase I (Sigma) was followed by a 
reverse transcription reaction using the High Capacity cDNA Reverse Transcription Kit 
from Applied Biosystems. The resulting copy DNA (cDNA) was enumerated with 
quantitative PCR using a Smart Cycler (Cepheid) and virulence factor gene assays.  
 
Quantitative PCR. VvhA was quantified using gene specific primers (vvhAF 5’-
TGTTTATGGTGAGAACGGTGACA-3’ and vvhAR 5’- 
TTCTTTATCTAGGCCCCAAACTTG-3’) and a probe labeled at the 5’ end with Texas 
Red and at the 3’ end with BHQ1 (5’-CCGTTAACCGAACCACCCGCAA-3’) (78). 
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The reaction mixture (20 μl) consisted of 4 μl template DNA (different concentrations), 
1 X PCR Buffer, 1 μM each primer, 250 nM probe, 200 nM dNTPs, 2.5 mM MgCl2, 1 X 
BSA (bovine serum albumin), and 1 U Taq DNA polymerase (Roche). Thermal cycling 
was performed using a two-step PCR protocol: 50°C for 2 min, 95°C for 10 min and 40 
cycles of 95°C for 15 s and 60°C for 1 min. 
CPS allele 1 was quantified using gene specific primers (HP1F 5’TTTGGGAT 
TTGAAAGGCT TG-3’ and HP1R 5’- TTTGGGATTTGAAAGGCTTG-3’) adapted for 
qPCR from Han et al. (41) and Sybr Green intercalating dye. The reaction mixture (20 
μl) consisted of 2-4 μl DNA template (different concentrations), 1 μM each primer, 2.5 
mM MgCl2, 1 X BSA and 10 μl of IQ Sybr Green Supermix (BioRad) that contains Taq 
DNA polymerase, and dNTPs. Thermal cycling was performed using a three-step PCR 
protocol: 30 cycles of 95°C for 90 s, annealing at 50°C for 60 s, and extension at 72°C 
for 60 s. Melt curve analysis was conducted from 60°C to 94°C at the increments of 
0.2°C per second. 
Standard curves were created in the Smart Cycler according to manufacturer 
instructions with the same primer sets (and probe) using cDNA from genomic DNA 
extracted from graduated concentrations (10
1
, 10
2
, 10
3
, 10
4
, 10
5
, 10
6
, 10
7
) of V. 
vulnificus strain FLA 8869. Counts (CFU) of V. vulnificus were generated by the 
standard curve and any dilutions were figured into the back calculation to the original 
DNA extraction volume. 
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 Biofilm assay. The production of biofilm by different strains of V. vulnificus was 
determined using a modified crystal violet staining method (218). After the 48 hr 
incubation under the desired conditions, the culture medium in the borosilicate glass 
tubes was gently poured out as not to disturb the biofilm ring. Each tube was gently 
washed four times with 2% NaCl to remove any non-adhered cells. Crystal violet (0.1%; 
850 μl) was added to tubes and incubated 40 minutes at room temperature. Afterwards, 
the unbound crystal violet was carefully decanted and tubes were rinsed thoroughly 3-4 
times with 2% NaCl to remove the unbound dye. Biofilm-bound crystal violet was 
eluted with 600 μl of 98% ethanol for 10 minutes. Aliquots (100 μl) of the eluted dye 
were transferred to 96 well plates and absorbance was measured at 570 nm using a 
Synergy 2 Multi-Mode Microplate Reader (Biotek). When necessary, the eluted dye was 
diluted with ethanol for measurements and the final absorbance value was multiplied by 
the dilution factor after subtracting the OD reading from the control tubes.  
 
Cell density. Bacterial density (cells/ml) was determined at OD600 nm with a 
Synergy 2 Multi- Mode Microplate Reader (Biotek). To convert OD to cell counts, V. 
vulnificus in aliquots were stained with DAPI (4', 6-diamidino-2-phenylindole), filtered 
onto 0.2 μm polycarbonate membranes, and then counted with epifluorescence 
microscopy using a Zeiss Axioplan 2 microscope (Zeiss). 
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Results 
Biofilm. By 4 h, biofilm rings were visible on glass tubes at the broth/air 
interface (Fig 20A). However, biofilm formation at 24°C and 37°C were markedly 
different. At 24°C, biofilm grew steadily from 4 h to 24 h reaching an optical density of 
extracted crystal violet (OD570 nm) of 22 as cell replication entered the stationary phase. 
At 37°C biofilm formation peaked at 8 h, during the logarithmic growth phase of cell 
replication, with an OD570 nm of extracted crystal violet of 16, and then decreased to an 
OD570 nm of 8 by 24 h as cells entered the stationary phase of growth (Fig. 20A).  
 
Cell replication. During biofilm formation at 24°C, cell density (Fig. 20A) 
increased rapidly from 3.1×10
5
±4.2×10
4
 cells/ml at 6 h to 3.9×10
6
±1.40×10
5
 cells/ml at 
8 h (i.e. logarithmic growth phase), increased to 4.5×10
6
±7.0×10
4
 cells/ml at 10 h, then 
decreased slightly to 4.1×10
6
±14.0×10
4
 cells/ml at 24 hr (i.e. stationary growth phase). 
In planktonic form, cell density (Fig 20D) was a factor of 10 lower than the biofilm 
culture by 4 h (3.0×10
5
±0 cells/ml) but rapidly increased to 3.0×10
6
±2.8×10
4
 cells/ml by 
10 h (i.e. logarithmic phase) and remained at that density until 24 hr (stationary phase).  
At 37°C, during biofilm formation, cell density (Fig. 21A) increased 10 fold from 
1.0×10
6
±0 cells/ml at 4 h to 1.5×10
7
±3.8×10
5
 cells/ml at 24 h. Planktonic cell density 
was three-fold higher at 4 h than in the biofilm incubation (Fig. 21D). Cell density 
increased rapidly from 3.1×10
6
± 8.3×10
4
 cells/ml at 4 h to 2.4×10
7
±7.0×10
3
 cells/ml at 
12 h and then decreased to 2.1×10
7
±3.5×10
5
 cells/ml by 24 h. Unlike biofilm production 
at 24°C, biofilm production at 37°C peaked at 8 h and then deteriorated steadily by 24 h.  
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Expression of vvhA. During biofilm formation at 24°C, vvhA gene expression 
(Fig. 20B) was low at 4 h (1.2×10
3
±2.7×10
2
 mRNA copies/ml) and 6 h 
(1.4×10
3
±2.5×10
2
 mRNA copies/ml) but increased three-fold by 8 h (4.3×10
3
±2.9×10
2
 
mRNA copies/ml), increased another three-fold by 10 h (1.2×10
4
 ±1.6×10
3
 mRNA 
copies/ml) and increased another four-fold by 24 h (5.1×10
4
±6.3×10
3
 mRNA copies/ml). 
Expression of vvhA had a strong correlation with biofilm formation (linear regression 
R
2
=0.89; p<0.0001).  In the planktonic incubation, vvhA expression (Fig. 20E) increased 
from 1.0×10
3
±3.3×10
1
 at 4 h to 8.3×10
3
± 6.9×10
2
 mRNA copies/ml at 10 hr. By 24 h, 
vvhA expression increased 17-fold to 1.4×10
5
±1.7×10
4
 mRNA copies/ml. In the first 10 
hours, rate of vvhA gene expression during biofilm formation was 1.9×10
3
 mRNA 
copies/ml/h compared to 1.2×10
3
 mRNA copies/ml/h in the planktonic incubation. 
However by 24 h vvhA expression in the planktonic incubation was more than double 
that of the biofilm incubation even though the cell density in the biofilm incubation was 
roughly 1.5 times higher. Highest expression of vvhA, in both the biofilm and planktonic 
incubations, occurred at 24 h. Normalization of mRNA copies/ml to individual bacterial 
cells (Table 25) revealed and up-regulation of vvhA expression at 4 h (1.07±0.00-fold), 
however between 4 and 24 h expression was down-regulated as much as (3.81±0.39-
fold).  
At 37°C, vvhA expression during biofilm formation (Fig. 21B) was already 
3.0×10
6
±1.0×10
5
 mRNA copies/ml at 4 h, 10
3
 mRNA copies/ml higher than at 24°C, but 
then decreased gradually to 8.5×10
5
±2.9×10
4 
mRNA copies/ml by 12 hr as the biofilm 
deteriorated. However, between 12 and 24 hr, as biofilm production continued to 
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decrease and cell density increased to 1.5×10
7
±3.8×10
5
, expression of vvhA increased 
almost 4-fold to 3.1×10
6
±6.0×10
3
 mRNA copies/ml. In the planktonic cells, vvhA 
expression was 2.4×10
6
±1.1×10
5 
mRNA copies/ml at 4 h, similar to the biofilm 
incubation, and increased slightly to 3.0×10
6
±1.6×10
5 
mRNA copies/ml by 12 h then 
decreased rapidly to 2.1×10
5
±9.2×10
4 
mRNA copies/ml at 24 h as cell replication 
entered the stationary phase, likely due to decrease of nutrients in the incubation media 
(Fig. 21E). In contrast to the 24°C incubation, vvhA expression was up-regulated in the 
biofilm incubation (Table 25). The highest up regulation occurred at 4 h (3.78±0.12-
fold) when biofilm production was lowest. At 12 h, as the biofilm began to deteriorate, 
there was a down-regulation (-1.15±0.35-fold) but by 24 h expression was up-regulated 
again (2.10±0.00-fold) as the biofilm continued to deteriorate and density of planktonic 
cells increased.  There was no correlation between vvhA expression and biofilm 
formation at 37°C (R
2
=0.17, p=0.1401). 
 
Expression of CPS allele 1. During biofilm formation at 24°C, CPS allele 1 
expression (Fig. 1C) decreased during logarithmic phase growth of cells (between 4 and 
12 h; 1.0×10
5
±4.6×10
3
 to 4.1×10
3
±1.6×10
3
 mRNA copies/ml, respectively) then 
increased approximately 400-fold to 1.5×10
6
 ±1.0×10
5
mRNA copies/ml by 24 h. 
However, in the planktonic culture, CPS allele 1 expression (Fig. 1F) increased during 
logarithmic phase (between 4 and 8 h; 1.2×10
6
±1.5×10
5
mRNA copies/ml to 
1.7×10
6
±3.0×10
5
 mRNA copies/ml, respectively) but then decreased eight-fold to 
5.9×10
5
±7.1×10
4
 mRNA units/ml by 24 h. In the biofilm incubation, normalization of 
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mRNA copies/ml per cell revealed an up-regulation of 1.5±0.18-fold at 4 h (Table 25). 
At 8 h there was a major down-regulation of 74.42±42.16-fold and a further down-
regulation of 453.76±193.32-fold by 12 h. However, by 24 h, expression was up-
regulated 1.88±1.07-fold as biofilm production peaked. Expression of CPS allele 1 was 
not correlated with biofilm production (R
2
=0.0363, p=0.5982).  
At 37°C, CPS allele 1 expression during biofilm formation (Fig. 21C) was high 
and constant at ~4.50×10
7
 mRNA copies/ml from 4 to 8 h but then decreased gradually 
to 3.94×10
7
±4.24×10
5
 by 24 h as the biofilm deteriorated. In the planktonic incubation, 
expression of CPS allele I was similar to that in the biofilm incubation at 4 h (4.48×10
7
 
±8.75×10
5
 mRNA copies/ml) but decreased rapidly between 4 and 8 h to 3.31×10
5
 
±2.74×10
4
 mRNA copies/ml and decreased further to 1.40×10
2
 ±3.07×10
1
 mRNA 
copies/ml by 24 hr as the cells entered stationary phase. In the biofilm incubation CPS 
allele 1 expression was up-regulated 1.69±0.05-fold at 4 h and increased to an up-
regulation of 4.03×10
5
 ±4.34×10
3
 by 24 h compared to the planktonic incubation.  
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Figure 20. V. vulnificus isolate FLA 8869 incubated at 24°C for 24 h: A) cell density (cells/ml) and biofilm 
formation, B) vvhA expression (mRNA copies/ml) and C) CPS allele 1 expression (mRNA copies/ml) 
during biofilm formation; D) cell density (cells/ml), E) vvhA expression (mRNA copies/ml) and F) CPS 
allele 1 expression (mRNA copies/ml) in planktonic form.  
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Figure 21. V. vulnificus isolate FLA 8869 incubated at 37°C for 24 h: A) cell density (cells/ml) and biofilm 
formation, B) vvhA expression (mRNA copies/ml) and C) CPS allele 1 expression (mRNA copies/ml) 
during biofilm formation; D) cell density (cells/ml), E) vvhA expression (mRNA copies/ml) and F) CPS 
allele 1 expression (mRNA copies/ml) in planktonic form. 
 
 
 
 
O
D
5
7
0
n
m
 
A 
B 
D 
E 
C
 
F 
 114 
 
 
Table 25. Up (+) or down (-) regulation (fold difference) of 
vvhA and CPS allele 1 expression normalized to individual cells 
during biofilm formation.  
Temperature Hour vvhA CPS allele 1 
24°C 
4 +1.07±0.00 +1.50±0.18 
6 -3.43±1.75 ND 
8 -3.50±2.96 -74.42±42.16 
10 -0.97±0.13 -453.76±193.32 
24 -3.81±0.39 +1.88±1.07 
    
37°C 
4 +3.78±0.12 +1.69±0.05 
6 +3.45±0.56 ND 
8 +1.87±0.63 +258.83±2.42 
12 -1.15±0.35 +1.25×10
4
±1.23×10
2
 
24 +2.10±0.00 +4.03×10
5
±4.34×10
3
 
 
 
Discussion 
Here we report a comparative transcript analysis of the vvhA and CPS allele 1 
expression of clinical V. vulnificus cells grown in a biofilm and in cells grown 
planktonically at 24°C and 37°C. We compared the expression of these genes at two 
temperatures because, in our previous study, V. vulnificus was shown to produce robust 
biofilms at 24°C typical of the marine environment and produced moderate biofilms at 
37°C, the temperature of the human host. 
During biofilm formation at 24°C, vvhA expression per cell was down-regulated 
by almost 4-fold at 24 hr compared to expression in planktonic cells likely because 
cellular energy was devoted to biofilm formation rather than toxin production. 
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Interestingly, vvhA expression was positively correlated with biofilm formation (R
2
=89; 
p<0.0001) indicating a possible co-regulation. It is important to note that even though 
expression of vvhA was down-regulated during biofilm formation at 24°C , it was 
nonetheless expressed and demonstrates that the biofilm form of V. vulnificus is still 
virulent, albeit less virulent than planktonic cells.  
At 37°C, vvhA expression in the biofilm incubation at 4 h was roughly 3-fold 
higher than expression at 24°C. And, in contrast to the down-regulation observed in the 
24°C incubation, expression of vvhA per cell during biofilm formation at 37°C was up-
regulated compared to planktonic cells (Table 25). Like V. cholerae, V. vulnificus 
appears to be more virulent in biofilms than in planktonic form at the temperature of the 
human host (50) and could explain the rapid infection rate of 24 to 48 h. Interestingly, 
vvhA expression per cell increased 3-fold between 12 and 24 h as the biofilm 
deteriorated and planktonic cell density increased. Again, the decrease in vvhA 
expression as the biofilm deteriorated indicates a possible co-regulation of biofilm and 
hemolysin/cytolysin production. In V. cholerae, cholera toxin and biofilm production are 
positively co-regulated by the VieS/A/B signal transduction system (239, 240). And in 
Bordetella bronchiseptica, another human pathogen, a two component signal 
transduction system (BvgA/S) controls both biofilm formation and virulence (241). The 
up-regulation of vvhA expression at 37°C compared to the down-regulation at 24°C 
during biofilm formation indicates that production of hemolysin/cytolysin is stimulated 
at higher temperature (i.e. that of the human host) and emphasizes that the biofilm form 
may be the preferred form of V. vulnificus in the human host.  
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CPS has been demonstrated to be essential for adherence of bacterial cells to 
surfaces (236, 237). We observed that in the biofilm incubation at 24°C, expression of 
CPS allele 1 was up-regulated at 4 h as the cells were attaching to the glass. 
Interestingly, expression at 24°C was down-regulated as the biofilm developed further 
indicating that CPS is not essential for intermediate biofilm formation. But by 24 h as 
the biofilm matured, CPS allele 1 expression was up-regulated again which seems to 
confirm the suggestion by Lee et al. (238) that CPS plays a critical role in determining V. 
vulnificus biofilm size by restricting continual growth of mature biofilms. At 24°C, there 
was no correlation between biofilm formation and CPS allele 1 expression however in 
early and late stages of biofilm formation CPS appears to be an important component of 
biofilm architecture in V. vulnificus, as indicated by our data. In the planktonic 
incubation, CPS allele 1 expression was highest in the first 8 h during logarithmic phase, 
and then decreased 8-fold by 24 h as cells entered the stationary phase. This pattern is 
similar to a study by Wright et al. (97) who observed that expression of CPS varied with 
the growth phase, increasing during logarithmic growth and declining in stationary 
culture. Differences between expression of CPS allele 1 in biofilm and planktonic 
incubations provide insights into the different functions of CPS.   
 Compared to the 24°C incubation, expression of the CPS allele 1 gene at 37°C 
was ~50× higher during biofilm formation indicating that CPS is an important 
component of biofilm in V. vulnificus. The up-regulation of CPS allele 1 expression at 
the peak of biofilm formation and during deterioration of the biofilm agrees with our 
observation at 24°C that CPS controls the size of the mature biofilm (Fig. 21C and Table 
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25). Interestingly, CPS allele 1 expression in the planktonic cells decreased as cell 
number increased. This is counter to what is known about CPS as protection from host 
immune response. One would expect CPS production to increase with increasing cell 
replication. This observation and the up-regulation of CPS allele 1 in the biofilm 
incubation emphasize the potential preference of the biofilm form of V. vulnificus in the 
human host rather than planktonic form. Preference for the biofilm form could also 
explain the increased virulence of clinical strains versus environmental strains in mice 
(23).  
 The results of this study differ from a previous study of biofilm formation in V. 
vulnificus. Joseph and Wright (45) observed that CPS inhibited adherence of planktonic 
cells to glass as well as biofilm formation. These differences may be due to alterations in 
incubation conditions (i.e. temperature, static vs. shaking, substrate). We observed the 
formation of thick, robust biofilms during shaking as compared to static incubation that 
was used by Joseph and Wright (45). And, strain differences also affect biofilm 
formation. In our previous study, significant strain to strain differences in biofilm 
production by clinical strains of V. vulnificus.  
 
Conclusions. The genes encoding for the virulence factors, hemolysin/cytolysin 
(i.e. vvhA) and capsular polysaccharide (i.e. CPS allele 1), during biofilm formation 
revealed that their expression was influenced by maturity of the biofilm as well as by 
temperature. Expression was also up-regulated at 37°C during biofilm formation 
indicating that biofilm may be the preferred form of V. vulnificus in the human host. In 
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addition to avoidance of host immune defenses, CPS is also an important component of 
V. vulnificus biofilm and affects adherence and size of biofilm. The results of this study 
indicate that the biofilm form may be important in the life phases of V. vulnificus both in 
the marine environment and in the human host.  
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CHAPTER VII 
 
SUMMARY AND CONCLUSIONS 
Understanding the environmental factors influencing virulence of V. vulnificus is 
of utmost importance in reducing human exposure to this deadly pathogen. Knowledge 
of the seasonal occurrence and life cycle offers clues to predicting the presence of more 
virulent clinical and less virulent environmental strains in oysters, other sea life, and 
seawater.  
 
Seasonal variation of virulence 
Chapter III examined how seasonal changes in temperature and salinity affect 
virulence of V. vulnificus in oysters. Since the discovery of more virulent clinical and 
less virulent environmental strains of V. vulnificus, identification of virulence factors to 
differentiate these strains has been the focus of numerous studies (37, 86, 97, 100, 178-
180). Molecular methods such as PCR assays targeting virulence indicator genes proved 
to be the most effective for differentiation (24, 25, 40, 181-183). However these assays 
were used primarily with isolated strains and enumeration depended upon enrichment 
and streaking onto selective-differential agars. The development of quantitative PCR 
assays for virulence indicator genes has allowed for not only detection but also 
enumeration of clinical and environmental strains in environmental samples, thus 
eliminating the need for isolation. In Chapter III, quantitative PCR assays for 16S rRNA 
type A/B and the clinical allele of the virulence correlating gene (vcgC) were used to 
 120 
 
 
determine the seasonal occurrence of clinical and environmental strains of V. vulnificus 
in oysters rather than screening individual isolate cultures for virulence genes. 16S 
rRNA type A targets environmental strains and 16S rRNA type B targets clinical strains. 
VcgC targets clinical strains. The null hypothesis that there is no seasonal variation of 
clinical and environmental strains in environmental samples was disproven. Strong 
seasonality of clinical strains of V. vulnificus environmental strains was observed in 
oysters. Environmental strains dominated the pool of V. vulnificus from April to June as 
water temperatures gradually rose from 18 to 30°C and salinities increased from 22 to 27 
PSU but were then succeeded by clinical strains from July through September when 
water temperatures were sustained at 30°C or above and salinities rose above 27 PSU. 
The hypothesis that the vcgC gene can accurately detect clinical strains in environmental 
samples was proven. The occurrence of the vcgC gene correlated strongly with 
occurrence of the 16S rRNA type B allele, the other virulence indicator for clinical 
strains. The use of two virulence indicators offered more conclusive evidence for 
detection of clinical strains. The seasonality and prevalence of clinical strains during 
warmer months observed in this study is in good agreement with Lin and Schwarz (53) 
who examined 16S rRNA allele types in Galveston Bay oysters and seawater.  In 
contrast, Warner and Oliver (182), who examined the seasonal occurrence of clinical and 
environmental isolates in oysters and seawater from North Carolina and Florida, found 
equal numbers of both strains in seawater but a predominance of environmental strains 
in oysters throughout the year. Like the current study, they did find that clinical strains 
increased in number in both oysters and seawater as water temperatures increased. 
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However, another study (242) examined market oysters from around the U.S. and found 
higher percentages of clinical strains in Gulf Coast oysters (up to 60%), where seawater 
temperatures are warmer, than in East Coast oysters (up to 18%) throughout the year. 
This study concluded that most foodborne V. vulnificus infections in the U.S. were from 
Gulf Coast oysters. This is a reasonable conclusion since there are also higher numbers 
of V. vulnificus in Gulf Coast oysters (>10
3
 per g) than in East Coast oysters (10
2
 per g) 
(15) due to warmer water temperatures.  
 
Conclusions. The current study and others demonstrate conclusively that 
temperature and salinity have a strong influence on selection for clinical or 
environmental strains of V. vulnificus. This finding has implications for increase of more 
virulent strains of vibrios due to global climate change (243-246), which have already 
been observed in V. cholerae (247).  
 
Selection of enrichment media for more virulent strains  
Most studies of the virulence of V. vulnificus in environmental samples have 
relied upon isolate cultures. Isolation methods typically involve an overnight enrichment 
in alkaline peptone water (APW), having a salinity of 10 PSU, that selects for halophilic 
bacteria (197). Enrichment is followed by streaking onto selective-differential agars and 
picking of single isolate colonies. In Chapter III, oyster samples were enriched for 20 h 
in APW prior to screening with quantitative PCR for virulence genes. This enrichment 
brought into question the potential for APW to select for clinical or environmental 
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strains of V. vulnificus, thus skewing the data. The potential selection for one strain or 
the other by different enrichment media was tested in Chapter IV. APW, Brain Heart 
Infusion Broth (BHIB), and Luria Bertani Broth (LB) were adjusted to the same salinity 
and inoculated with Galveston Bay seawater samples collected in the spring (March), 
late summer (September), and fall (November). This study found that BHIB with its 
higher iron content selected for clinical strains however the starting inoculum of clinical 
strains was important. In March when the occurrence of clinical strains was low or non-
detectable, there was no significant enrichment. In September and November when the 
occurrence of clinical strains in seawater was presumably higher, significant preferential 
selection by BHIB was observed. Laboratory testing with isolate cultures found that 
enrichment with APW did not alter the ratio of environmental to clinical strains but 
BHIB preferentially selected for the clinical isolate. Therefore, percentages of clinical 
out of total V. vulnificus observed by enrichment with APW were a truer representation 
of the natural population in the seawater samples. This finding disproved the hypothesis 
that APW does not select equally for clinical and environmental strains. And the 
hypothesis that BHIB with its high iron content selects preferentially for clinical strains 
was proven.  
 
Conclusions. The selective enrichment of BHIB for clinical strains indicates that 
iron plays an important role in the infection of the human host. Seasonality of Vibrio 
vulnificus clinical and environmental isolates influenced the starting inoculum and 
ultimately the selective enrichment for clinical strains in all media tested.  
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Biofilm formation 
Chapter V examined biofilm production of clinical versus environmental isolate 
strains of V. vulnificus under different temperature, pH, and iron concentration 
conditions. Clinical strains were found to produce significantly more biofilm than 
environmental strains at 24°C versus 30°C or 37°C, thus disproving the hypothesis that 
clinical strains would produce more biofilm at 37°C, the temperature of the human host. 
The formation of robust biofilms at 24°C indicates that the biofilm form may be 
important for protection of clinical strains in the marine environment. V. cholerae forms 
thick biofilms 15°C and 25°C, temperatures encountered in the aquatic environment 
(159). V. cholerae also produces biofilm in vivo within the human host (49) and in vitro 
at 37°C but they are thinner and less structured (160). And, biofilm formation by V. 
cholerae is stimulated bile acids (162). Similarly, there was a significant trend for 
clinical strains of V. vulnificus to form more biofilm at acidic pH (5.5) than 
environmental strains, at both 24°C and 37°C, indicating that biofilm may be important 
for survival of clinical strains in the gastrointestinal tract of the human host. This finding 
supports the hypothesis that V. vulnificus produces more biofilm at acidic pH than at 
neutral or alkaline pH.  
 
Conclusions. Higher biofilm production appears to be a trait of clinical strains 
and could be considered a virulence factor. This study revealed that the biofilm form 
may be important in the life cycle and ecology of V. vulnificus, in particular for clinical 
strains.  
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Expression of virulence factors in biofilms 
Chapter VI examined the expression of hemolysin/cytolysin (i.e. vvhA) and CPS 
(i.e. CPS allele 1) genes during biofilm formation.  Expression was influenced by 
maturity of the biofilm as well as by temperature. At 24°C, vvhA expression was down-
regulated but at 37°C it was up-regulated by 10
5
-fold indicating that it is stimulated by 
higher temperature (i.e. that of the human host). The up-regulation at 37°C supports the 
hypothesis that V. vulnificus expression of the hemolysin/cytolysin gene (vvhA) will be 
higher during biofilm formation than in planktonic cells. 
CPS allele 1 expression at 24°C was up-regulated during the attachment phase of 
the biofilm, down-regulated during the growth phases of the biofilm and then up-
regulated again as the biofilm matured to control size of the biofilm. A similar pattern 
was observed at 37°C. Compared to planktonic cells, expression of CPS allele 1 was up-
regulated during biofilm formation and even deterioration emphasizing the importance 
of CPS in these processes. These findings disprove the hypothesis that CPS allele 1 will 
be suppressed during biofilm formation and increased in planktonic forms of V. 
vulnificus. 
 
Conclusions. The up regulation of expression of both genes at 37°C during 
biofilm formation indicates that biofilm may be the preferred form of V. vulnificus in the 
human host. In addition to avoidance of host immune defenses, CPS is also an important 
component of V. vulnificus biofilm and affects adherence and size of biofilm.  
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